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ABSTRACT
Infectious laryngotracheitis virus (ILTV; Gallid herpesvirus 1) causes upper respiratory
diseases in mainly chickens and exhibits 90-100% of high morbidity and up to 70% of mortality,
resulting in huge economic losses in the poultry industry worldwide.
To study host-ILTV interactions, the changes in genome-wide gene expressions in
response to wild-type and vaccine ILTV infections in primary chicken embryo lung cells were
investigated using microarray analysis. Results provide crucial insights into host cell pathogenic
and immunogenic responses against wild-type and vaccine ILTV infections. Using microarray
method and Ingenuity Pathway Analysis (IPA) bioinformatics tool, 273 and 306 differentially
expressed genes were identified responding to wild-type and vaccine ILTV infections,
respectively. Further integrated analysis to compare differentially expressed genes revealed that
eight host genes including coagulation factor II (thrombin) receptor-like 1 (F2RL1), bone
morphogenetic protein 2 (BMP2), inhibitor of NF-kB (IkB) kinase subunit beta (IKBKB)
interacting protein (IKBIP), thymidylate synthetase (TYMS), chromosome 8 open reading frame
79 (C8orf79), coagulation factor X (F10), prostaglandin-endoperoxide synthase 2 (PTGS2) and
neuropeptide Y (NPY) were regulated differently between wild-type and vaccine ILTV
infections in an opposite direction, suggesting that these host factors may play important roles in
host immune responses against ILTV infection. In addition, the transcriptome changes of ILTV
encoding genes were studied during infection time courses using quantitative PCR. In this study,
infected-cells polypeptide (ICP) 4 showed the highest expression level and UL21 and UL42
showed unique expression patterns, unlike most of the other ILTV gene which exhibited
continuous elevation of expression during lytic infection. Kinetic analysis of ILTV gene
expression in host cells may provide new knowledge to understand ILTV pathogenesis.
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CHAPTER 1.
LITERATURE REVIEW
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1. Herpesvirus
1.1. Herpesvirus virion structure and alphaherpesviurs
Herpesviruses share the same virion structure ranging from 130 to 300 nm in size.
Commonly, the virion includes a linear dsDNA genome in 100 to 110 nm icosahedral capsid
surrounded by tegument proteins [1]. The tegument proteins consisting of at least 20 viral
proteins play various roles in viral genome replication and the modulation of cellular responses
[2]. A host lipid layer with viral glycoproteins covering the tegument layer mediates attachment,
penetration and immune evasion.
According to the genome sequence, replication dynamics and latency site, the
Herpesviridae family is divided into three subfamilies; Alpha-, Beta- and Gammaherpesvirinae
[3]. In human herpesviruses, alphaherpesvirinae includes herpes simplex virus (HSV) type 1
[(HSV-1; human herpesvirus 1 (HHV-1)], HSV type 2 (HSV-2; HHV-2) and varicella-zoster
virus (VZV; HHV-3). Betaherpesvirinae includes human cytomegalovirus (hCMV; HHV-5),
HHV-6 (herpes lymphotropic virus and HHV-7. Gammaherpesvirinae includes Epstein-Barr
virus (EBV; HHV-4) and Kaposi’s sarcoma-associated herpesvirus (KHSV; HHV-8).
In animal herpesviridae, alphaherpesvirinae is categorized into genera of simplexvirus,
varicellovirus, mardivirus and iltovirus. Simplexvirus includes bovine herpesvirus 2 (BHV-2),
cercopithecine herpesvirus 1 (herpes B virus) and ateline herpesvirus 1. Varicellovirus genus
includes bovine herpesviurs 1 (BHV-1) and 5 (BHV-5), caprine herpesvirus 1, porcine
herpesvirus 1 (pseudorabies herpesvirus; SuHV-1), equine herpesvirus 1 (EHV-1), 3 (EHV-3)
and 4 (EHV-4), canine herpesvirus 1 (CHV-1), feline herpesvirus 1 (FVR-1) and duck
herpesvirus 1 (DEV-1). Mardivirus genus includes gallid herpesvirus (GaHV) 2 (Marek’s
disease virus; MDV) and 3 (GaHV-3 or MDV-2), and herpesvirus of turkeys (HVT). Iltovirus
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genus includes GaHV-1 (infectious laryngotracheitis virus; ILTV) and pittacid herpesvirus 1
(PsHV-1). Betaherpesvirinae has only one rahdinovirus genus including porcine herpesvirus 2.
Gammaherpesvirinae includes alcelaphine herpesvirus 1 (AIHV-1) and 2 (AIHV-2), bovine
herpesvirus 4 (BHV-4), equine herpesvirus 2 (EHV-2) and 5 (EHV-5) and murid herpesvirus 4
[murine gammaherpesvirus-68 (MHV-68)] [4].
Alphaherpesviruses initially infect epithelial cells such as skin cells, replicate quickly and
cause sores on the membranes of skin or mucous. Since the virus is neurotropic, the viruses
travel to the central nervous system (CNS) to establish latent infection in the ganglia of sensory
neurons without active virus replication. The latently infected viruses are reactivated by the
environmental changes of host such as ultraviolet (UV) light stimulation, the immunosuppression,
trauma of latently infected CNS and even social stress [5]. The alphaherpesviruses have been
used as a model to study other herpesviruses and host-virus interactions due to the rapid
replication [6]. Generally, betaherpesviruses produce progenies slower than other subfamilies
and latently infect leukocytes, while gammaherpesviruses propagate at variable rates and latently
infect only lymphocytes [7-9].

1.2. Herpesvirus life cycle
As an ancestor type of herpesviruses, the HSV-1 entry event follows three steps; the
sequential-, intermediate hemifusion- and a stable entry pore forming stages [10]. During the
sequential stage, herpesvirus entry is initiated by the interaction between the viral envelope
glycoproteins and host cellular surface receptors. Viral glycoprotein (g) C (gC) binds to heparan
sulfate on a cell surface. In turn, gD binds to one of three host cell entry receptors named
herpesvirus entry mediator (HVEM), nectin-1 and 3-O heparan sulfate to establish a strong
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attachment. In the hemifusion stage, gD changes its structural conformation and interacts with
the complex of gH and gL. At the last entry step, gB also interacts with the gH and gL complex
to form a pore for the viral capsid to enter into the host cell cytoplasm [10, 11].
The viral capsid in the cytoplasm moves to a nuclear entry pore on the nuclear membrane,
and the viral DNA is released into the nucleus through the capsid portal consisting twelve of
proteins encoded by UL6 genes [12, 13].
The DNA released into nucleus transcribes the genes in three stages: immediate-early
(IE), early (E) and late (L). In the IE stage, infected-cells polypeptide (ICP) 4 is mainly
expressed and functions as a transcriptional transactivator for other virus genes by binding to
viral promoters [14]. A cellular alpha trans-inducing factor (α-TIF) protein helps ICP4 to
regulate the viral transcription activity in the IE stage [15]. The viral proteins expressed in the E
stage play regulatory roles in virus genome replication. The most important E protein is the
virion host shutoff (VHS) protein encoded by UL41 genes since VHS blocks host protein
synthesis by cleaving host mRNA to support both viral genome replication and viral gene
expression [16, 17]. The proteins expressed during the L stage mainly function in capsid
formation and in packaging virus particles containing the virus genome, core and capsid proteins.
Herpesvirus maturation and tegumentation occur in the perinuclear space and in the cytoplasm,
respectively. Following two envelopment processes, including the egress of capsids from the
nucleus and the second envelopment from the Golgi, the enveloped virus particles are released
from infected cells [2, 18].

1.3. Latent infection
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During the HSV-1 latent infection in neuronal ganglia, viral genes named latency
associated transcripts (LAT) are expressed to suppress apoptotic cell death by producing miRNA
against apoptosis inducing cellular factors such as transforming growth factor-beta1 (TGF-β1),
mothers against decapentaplegic homolog 3 also known as (a. k. a.) SMAD family member 3
(SMAD3), trombospondin-1 [19-21], and caspase-8 and caspase-9 [22]. The herpesviral LAT
genes can also regulate viral genome replication to establish the latent infection in the infected
host [23, 24]. The function of ICP4 is inhibited by neuronal restrictive silencing factor (NRSF)
and human repressor element silencing transcription factor (REST) in the latent infection [25,
26]. The latently infected virus can be reactivated by the ICP0 and ICP4 from the dissociation of
NRSF in illness or physical stress conditions [27].

2. Infectious laryngotracheitis and infectious laryngotracheitis virus
2.1. Infectious laryngotracheitis
Infectious laryngotracheitis (ILT) is an acute respiratory disease in the avian species such
as chickens [28, 29], pheasants, peafowls [30-32] and turkey [33]. ILT is caused by the infection
of ILT virus (ILTV; Gallad Herpesvirus 1). Since the first report of fowl ILT in 1925 [34],
severe ILT outbreaks have been observed worldwide in Europe, Australia, New Zealand, China,
Southeast Asia and the United States where poultry productions are concentrated [35-40].
ILT partially induces the occlusion of the upper larynx and trachea, and intensive
inflammation [41]. Chickens in a mild stage of ILT show decreased egg production, watery eyes
by conjunctivitis, mild tracheitis, swollen infraorbital sinuses, and a mucoid nasal discharge [42],
while a severe stage of ILT induces severe sneezing and coughing, distressed open-mouth
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breathing, and bloody mucus [43, 44]. Chickens frequently shake head to remove the bloody
mucus since bird’s airway and trachea are filled with blood (Figure 1).

(A)

(B)

Figure 1. Clinical signs by ILTV infection.
(A) Swollen, watery eyes (http://www.worldpoultry.net/background/infectious-laryngotracheitis28ilt29-targets-broilers-7050.html). (B) Bloody trachea (left to right: severe, mild and normal)
(http://www.bellsouth.com.au/tech/respiratory%20disease%20in%20breeder%20flocks.html)

Clinical signs usually appear 6 to 12 days after exposure to ILTV [32, 38]. Though
chickens showing breathing difficulty and coughing with bloody mucus usually die within a few
days, chickens showing mild clinical signs recover in 10-14 days [45, 46]. The ILTV infection
through natural routes can be detected in tracheal tissues from 6 to 12 days, and latent infection
in the CNS is achieved at 7 days after an acute infection phase [47-49].
The latent infection in the trigeminal ganglion (TG) in the CNS was established by both
vaccine and challenge strains in an experimental study [50]. Though the sporadic ILTV spread is
unknown, reactivated ILTV replicates in the respiratory tract and virus can transmit from bird to
bird by contact [51]. The reactivation of latently infected ILTV from vaccinated flocks was
found in TG post 15 months vaccination [49, 52].
ILT causes high morbidity which is 90-100%, but the mortality varies from 10-20% but
can reach up to 70% [38, 45, 46]. The mortality and the decreased egg production by ILTV
6

infection cause economic losses in the poultry industry. Infected chickens serve as carriers which
are the main source of the transmission to uninfected chickens through respiratory routes by
coughing and sneezing. People working with ILTV-infected flocks can be candidates to spread
ILTV through contaminated materials such as footwear, clothes, vehicles, equipment and even
their hands [53].

2.2. Infectious laryngotracheitis virus
2.2.1. ILTV genome
ILTV is classified as a member of Iltovirus genus, Herpesviridae family. ILTV has a
linearized dsDNA, which is about 150kb in size, consisting of a unique long (UL) and a unique
short (US) region flanked by inverted repeat (IR) and terminal repeat (TR) regions (Figure 2) [44,
54-56].

Figure 2. Map of ILTV genome [57].

Since partial ILTV sequences were reported in the late 1980s [58], the first full-length
ILTV genome sequence was reported in 2006 by the assembly of sequences from six different
ILTV strains [59]. The ILTV genome contains unique five open reading frames (ORFs) named
7

ORF A, B, C, D and E located near a replication origin (ORIL) in the UL region that these ORFs
have distinct characteristics from other alphaherpesviruses (Figure 2) [60]. The ILTV genome
includes three origins for DNA replication as same as shown in other alphaherpesviruses. One
OriL is located in the UL region, and two identical ORIS are located in the IR and TR sequences
(Figure 2) [60]. ORIS has not been detected and was excluded in the first known ILTV genome
sequence due to its long palindromic sequence characteristic [59]. Of the entire 76 ILTV genes,
63 genes are homologs to those in HSV-1 [61], indicating translational proteins are inferred from
the similar structure between ILTV and HSV-1 (Table 1). Eleven conserved ORFs namely UL27,
UL44, US6, US8, US4, UL22, US7, US5, UL53, UL1 and UL10 encode glycoproteins of gB, gC,
gD, gE, gG, gH, gI, gJ, gK, gL and gM, respectively.
Very recently, the complete genome sequence of a single Austrailian commercial live
attenuated ILTV vaccine strain (Serva) is reported using high-throughput sequencing technology
[62]. The Serva ILTV genome encodes 80 predicted ORFs. UL and US regions included 65 and
9 ORFs, respectively, and IR and TR region have three ORFs each. The genome length of the
Serva strain was 152,628 bp in size with a G + C content of 48%. The nucleotide sequence is
96.5% identical to the previous mosaic ILTV genome sequence (NC_006623). Four regions,
including 528 bp sequences in the UL29, 594 bp sequences in the UL36, and two 1,563 bp
sequences in the repeat regions, which were not identified in the previously known mosaic
genome sequence, are newly determined. The size differences of the predicted protein products
are also detected in UL54, UL30, UL37 and UL38.

8

Table 1. Comparison of HSV-1 and ILTV genomes.
HSV
ICP34.5
ORF-P
ORF-O
ICP0
UL1
UL2
UL3
UL4
UL5
UL6
UL7
UL8
UL8.5
UL9
UL9.5
UL10
UL11
UL12
UL12.5
UL13
UL14
UL15
UL15.5
UL16
UL17
UL18
UL19
UL20
UL20.5
UL21
UL22
UL23
UL24
UL25
UL26
UL26.5
UL27
UL27.5
UL28
UL29
UL30
UL31
UL32

Time
IE
IE
IE
IE
L
E-L
L
L
E
L
L
E
L
E
L
L
L
E
?
L
L
L
?
L
L
L
L
L
L
L
L
E
L
L
L
L
L
L
L
E
E
L
L

Functions

ILTV (Matched)

gL
uracil-DNA glycosylase
(P) Nuclear protein
(P) Nuclear protein
Helicase-Primase complex
portal protein
Tegument
synthesis of RNA primer
DNA replication
ATPase and Helicase

UL1
UL2
UL3
UL4
UL5, UL8
UL6
UL7

gM
Tegument
Alkaline nuclease

UL10
UL11
UL12

PK
Protein folding
DNA cleavage and packing
(P) Capsid
(P) virion component
DNA cleavage and packing
VP23 (Capsid)
VP5 (Major capsid)
(P) Envelop protein

UL13
UL14
UL15

Tegument
gH
TK
Nuclear protein
Capsid (DNA packaging)
Scaffolding protein
Scaffolding protein
gB

UL21
UL22
UL23
UL24
UL25
UL26
UL26.5
UL27

DNA cleavage and packing
ICP8
DNA polymerase
Nuclear phosphoprotein
DNA cleavage and packing

UL28
UL29
UL30
UL31
UL32

9

UL9

UL17
UL18
UL19
UL20

ILTV (Unmatched)
UL-1
UL0
UL3.5
sORF4/3

HSV
UL33
UL34
UL35
UL36
UL37
UL38
UL39
UL40
UL41
UL42
UL43
UL43.5
UL44
UL45
UL46
UL47
UL48
UL49
UL49.5
UL50
UL51
UL52
UL53
UL54
UL55
UL56
ICP4
ICP22
US1.5
US2
US3
US3.5
US4
US5
US6
US7
US8
US8.5
US9
US10
US11
ICP47
LAT

Time
L
L
L
L
L
L
E
E
L
E
L
L
L
L
L
L
L
L?
L
E
L
E
L
IE
L
L
IE
IE
IE
L
L
L
L
L
L
L
L
L
L
L
L
IE

Functions
Capsid (DNA packaging)
Nuclear protein
VP26
Largest tegument
Tegument
VP19C
Ribonucleotide reductase
Ribonucleotide kinase
VHS
DNA polymerase
Membrane protein

ILTV (Matched)
UL33
UL34
UL35
UL36
UL37
UL38
UL39
UL40
UL41
UL42
UL43

gC
Membrane protein
VP11 and VP12
VP13 an dVP14
VP16 and á-TIF
VP22
Membrane protein (Possible) gN
dUTPase
Tegument
Helicase-Primase complex
gK
ICP27

UL44
UL45
UL46
UL47
UL48
UL49
UL49.5
UL50
UL51
UL52
UL53
UL54

Membrane protein
ICP4
ICP22

UL56
ICP4

(P) Membrane protein
PK

US2
US3

gG
gJ
gD
gI
gE

US4
US5
US6
US7
US8

Membrane protein
Tegument

US9
US10

ILTV (Unmatched)

gN

ICP47

The expression time and function of HSV-1 encoding genes were referenced from Fields
Virology (5th ed.) by David M. Knipe and Peter M. Howley [42].
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2.2.2. The unique characteristics of ILTV genome
ILTV has unique features and characteristics compared to other herpesvirus species.
UL3.5 located in ILTV genome between UL3 and UL4 is not presented in HSV-1, but is
conserved in alphaherpesviruses, including BHV-1, BHV-5 and PrV [63-65]. UL16 is not
contained in the ILTV genome though it is conserved in all other herpesvirus subfamilies [66,
67]. UL47, which is a major tegument protein located in the UL region of other
alphaherpesviruses [61], is present between US3 and US4 on the US region of ILTV genome
[68]. A large internal inversion is found uniquely in the UL region of the ILTV genome [60].
ILTV and PsHV-1 were classified as members of the Iltovirus genus of the Herpesviridae
family [59]. Both viruses have an identical inversion of TR region in between UL region and US
region, and a translocation of UL47 also has been discovered in both viruses [59]. Genes within
the US region [68], and ORF-A to ORF-E localized in the UL region are conserved in both ILTV
and PsHV-1 genomes [59, 60]. UL0 and UL(-1) of ILTV show high similarities in deduced
amino acid sequence indicating possible ancient duplication [69], while PsHV-1 has only UL(-1),
no UL0, in its genome [59]. In genealogy tree, ILTV and PsHV-1 might belong to separate
phylogenic branches in the herpesvirus family, which is confirmed by comparative analyses with
the viral amino acid sequences [70, 71]. All these results indicated that ILTV and the mammalian
alphaherpesviruses were separated from a common ancestor earlier than the separation into other
avian herpesviruses including MDV and HVT [57].

2.2.3. ILTV virion structure, morphogenesis and propagation
Electron micrographs of the reassembly of ILTV particles are very similar to HSV-1
(Figure 3). ILTV virion possesses the hexagonal nucleocapsids which are 80-100 nm in diameter,
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and the nucleocapsids are built with icosahedral symmetry and composed of 162 elongated
hollow capsomeres [72, 73]. A tegument and an outer envelope membrane containing viral
glycoproteins enclose an icosahedral capsid including a DNA-containing core [72, 73].

Figure 3. ILTV morphology by
electron microscopy [57]. (A)
Micrographs of entire cell and virus
micrographs; (B and C) Nuclear egress
and primary development; (D and E)
Assembly of tegument and secondary
envelopment in the trans-Golgi; (F and
G) Release of virions by exocytosis.
Bars indicate (A) 1 μm, (D) 500 nm, (E,
F and G) 300 nm and (B and C) 150
nm.

The morphogenesis of ILTV follows that of typical herpesvirus in infected cells (Figure 3)
[2, 18, 74]. The capsid formation and viral DNA inclusion occurs in the nucleus (Figure 3A and
3C) and are followed by the nucleocapsids transportation into the cytoplasm by envelopment at
the inner and outer leaflets of the nuclear membrane for the first budding (Figure 3B and 3C).
The cytoplasmic capsids surrounded by dense tegument are re-enveloped by the second budding
into the trans-Golgi (Figure 3D and 3E). Matured virions are released by exocytosis (Figure 3F
and 3G). A unique feature observed in ILTV infected cells during propagation is to produce
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many light (L) particles consisting only tegument and envelope without nucleocapsids, which
cannot be replicated (Figure 3D) [18, 74]. The low ILTV titers produce in tissue culture may be
due to the excessive production of non-reproducible ghost virion particles.
The in vitro propagation of ILTV was first reported on the choriallantoic membrane of
embryonated chicken eggs [75]. ILTV can be propagated in primary chicken embryo kidney
(CEK) and liver (CEL) cells [76]. Only one continuously growing cell line, chicken liver tumor
cell line (Leghorn male hepatoma; LMH), can propagate ILTV efficiently [77-79]. However, the
ILTV titers produced from LMH cells were critically lower than in use of CEK and CEL cells
(data not shown).
Cytopathic effects (CPE) showing syncytia and inclusion bodies were detected during
ILTV infection in permissive chicken cells at several hours post infection (hpi) [80], and plaques
formed by cell lysis were developed 3 to 5 days post infection (dpi). Though the replicative life
cycle of ILTV has not been studied sufficiently, it may be similar to that of other
alphaherpesviruses such as HSV-1 [67]. The first infectious progeny viruses were detected at 8
to 12 hpi, and maximum number of ILTV replication was reached 24 to 30 hpi [81]. The
regulation of ILTV gene expression and DNA replication appeared to follow the way of typical
herpesviruse propagation in infected cells [81-83].

2.2.4. Diagnosis of ITLV
ILTV detection methods include virus neutralization by ILTV-specific antibodies,
immunodiffusion, indirect immunofluorescence assay (IFA), enzyme linked immunosorbent
assays (ELISA) [48, 76, 84-89]. The gJ- and gC-specific monoclonal antibodies (MAbs) were
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developed for the use of diagnostic purposes, such as IFA, immunohistochemistry,
immunoelectron microscopy, radioimmunoprecipitations and Western blot analyses [57].
Recently, faster, more accurate and more sensitive methods have been developed to
detect ILTV DNA. The methods include dot-blot hybridization using cloned DNA probes [90],
in situ hybridization from ILTV infected chickens [91], PCR [88, 92-94], quantitative real-time
PCR (qPCR) [95] and restriction fragment length polymorphism polymerase chain reaction
(PCR-RFLP) [96-99].

2.2.5. ILTV proteins and functions
Generally, herpesviruses produce pathogenically important proteins such as envelop,
tegument, capsid, glycoproteins and even non-structural proteins such as thymidine kinase (TK)
and transcriptional regulator.
Among 11 glycoproteins encoded in the HSV-1 genome, four glycoproteins, gB, gD, gH
and gL which are encoded by UL27, US6, UL22 and UL1, respectively, have critical roles for
HSV-1 entry into host cells. The gD binds to TNFRSF14/HVEM, PVRL1 and 3-O-sulfated
heparan sulfate, which are entry receptors for HSV-1, and provokes the fusion between host
membrane and viral envelop. The gB interacts with a membrane fusion protein, and gH and gL
forms heterodimers with gD and gB proteins [100-102]. Moreover, these four glycoproteins are
related to the early innate and adaptive immunity of infected host cells [103]. Likewise, ILTV
encodes 11 glycoproteins including gL, gM, gH, gB, gC, gK, gG, gJ, gD, gI and gE and a
thymidine kinase (TK), and those proteins may critically function in viral virulence and
replication.
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2.2.5.1. Glycoprotein C (gC)
The gC of alphaherpesviruses is highly conserved and critically functions in virus
attachment through the interaction with heparan sulfate proteoglycan (HSPG) chains on the host
cell membrane [67, 104]. However, ILTV gC does not bind to heparan sulfate due to the lack of
the heparan binding site of about 100 amino acids at the N-terminal end. Thus, ILTV may use
different mechanisms from those used by other herpesviruses [105, 106].

2.2.5.2. Glycoprotein J (gJ)
The ILTV gJ, which was previously known as gp60 due to 60,000 D in weight, is
encoded at the same position (US5) of HSV-1 [89, 107]. The gJ gene is not found in most other
alphaherpesvirus, but EHV-1 has envelope glycoprotein 2 (gp2) which is highly homologous to
ILTV gJ sequence [108, 109]. The gJ is processed by N- and O-linked glycosylation and may
function in cell-to-cell spread and in the attenuation of ILTV which were shown using ΔgJ ILTV,
a gJ-deficient form [110].

2.2.5.3. Glycoprotein B (gB)
The gB is highly conserved and functionally similar to that of other herpesviruses [111,
112]. The gB was processed by the addition of N-linked glycosylation and two subunits were
produced by proteolytic cleavage [113]. As a fusion protein, gB collaborates with gH and gL for
viral entry into the cells [114-117].

2.2.5.4. Glycoprotein M (gM) and glycoprotein N (gN)
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In many herpesviruses including ILTV, gM and gN encoded by UL10 and UL49.5 in the
ILTV genome, respectively, have to form a heterodimer to be functional [110]. The gN protein
of ILTV is O-glycosylated like the gB protein of other herpesviruses, whereas the gM protein of
ILTV is not glycosylated, which is different from other herpesviruses [66]. But, both gN and gM
proteins are dispensable for viral replication in cultured cells [66, 110].

2.2.5.5. Glycoprotein G (gG)
The gG, which is encoded by the ILTV US4 gene and conserved among other
alphaherpesviruses, is not assembled into virus particles [83] but is secreted from infected cells
and possibly has immunomodulating functions [118]. In vivo, gG is a virulence factor of ILTV,
but dispensable for virus replication suggesting that gG may become a candidate for ILTV
vaccine production [119-121].

2.2.5.6. Glycoprotein E (gE) and glycoprotein I (gI)
The gE and gI are non-essential proteins and also form a heterodimer for a functional
protein. The gE and gI play a role in cell-to-cell spread [122] to the same as those in HSV-1 [123,
124].

2.2.5.7. Glycoprotein L (gL) and glycoprotein H (gH)
The gL is essential for the replication of ILTV and forms a complex with gH for viral
replication [63]. Moreover, gL is not independently anchored with gH in the cell membrane or
on the virus envelope [125]. The function of gH in ILTV is not clear. However, based on other
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alpharherpesvirus studies, gH of ILTV may be associated with virus entry and cell-to-cell spread
and may be nonessential for egress [18, 126].

2.2.5.8. Glycoprotein D (gD) and glycoprotein E (gE)
The gD and gE of ILTV have not been studied, but it has been shown in DEV-1 infection
that gD plays an important function in virus entry and gE is required for cell-to-cell spread [127].

2.2.5.9. Thymidine kinase (TK)
TK functions in DNA synthesis in living cells through catalyzing deoxythymidine to
deoxythymidine 5’-phosphate using adenosine 5’-triphosphate (ATP) [128, 129]. TK encoded
from the UL23 gene of ILTV affects the virulence of ILTV in infected cells but not viral
replication [130, 131]. TK plays an important role in the reactivation and subsequent replication
of alphaherpesviruses from latently infected ganglia [132]. Therefore, TK may become a
candidate to study the mechanisms of latent infection, reactivation and virulence of ILTV, and
vaccine development.

3. Genomics approaches in host-virus interaction
This thesis mainly focuses on the host-ILTV interactions using microarray and qPCR.
Moreover, newly developed bioinformatics programs have been used to analyze extensive data
produced from the microarray and qPCR.
3.1. Microarray
A microarray is a powerful tool to compare the expression of massive number of
interesting genes simultaneously. The current microarray concept, which evolved from Southern
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blotting method, was first introduced by Maskos in 1992 [133], and the pre-existing approaches
for microarray had been reported from 1982 to 1991 [134-137]. Finally, miniaturized
microarrays were first utilized in 1995 [138], and a complete genome-wide microarray for
eukaryote was developed in 1997 [139]. Cumulative set of DNA probes are utilized on a solid
slide, and each probe can be hybridized with a specific target cDNA or cRNA. The expression
level is quantified by labeling chemiluminescence dyes such as cyanine 3 (Cy3) and cyanine 5
(Cy5). A microarray slide contains up to hundreds of thousands different probes. Current
microarray technology is being used for numerous applications such as gene expression profiling
[140], comparative genomic hybridization [141] and SNP detection [142].

3.2. Application of microarray in herpesvirus-host interaction
Microarrays have been used to identify host responses against numerous viruses
including herpesviruses such as hCMV and KSHV [143], EBV [144], ILTV [140], VZV [145],
MDV [146, 147], HSV-1 [148] and HSV-2 [149].
Host cellular gene expressions in response to herpesvirus infection differed depending on
virus types [150]. In case of HVT infection, microarray results showed that cellular gene
expression on functions of signal transduction, transcription, scaffolding proteins and the
cytoskeleton were regulated differentially in chicken embryo fibroblasts (CEF) [151].
Microarrays on host gene expression with HSV-1 infection reported that IFN-induced antiviral
state was blocked through IFN-independent intracellular mechanism [152], and those genes on
protein processing, carbohydrate processing, cell adhesion, apoptosis, and host defense and
immune response were changed significantly in HSV-1 latent trigeminal ganglia (TG) [153]. In
MDV infected CEF cells, data of microarray showed altered host gene expression on
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macrophage inflammatory protein, interferon response factor 1, interferon-inducible protein,
quiescence-specific protein, thymic shared antigen 1, MHC class I and II, beta-2 microglobulin,
clusterin, interleukin (IL) 13 receptor alpha chain, ovotransferrin and a serine/threonine kinase in
CEF cells [154]. Also, the critical changes of the gene expression of IL6, IL12 and IFN-α were
observed in MDV-infected chicken brain, and IL18 was significantly expressed in only MDassociated transient paralysis (TP) [155]. Differential gene expression of chemokine AH221, Bcell marker BU-1, IgG, igA, IgM, MHC class II beta chain, granzyme A (GZMA) and signal
transducers and activators of transcripition 2 (STAT2) genes were found in microarray assay on
the resistance or susceptible chickens against MDV infection [156]. The results, found in
microarray analysis on EBV infection, showed altered functions in signal transduction,
transcription, protein biosynthesis and degradation, cell motility, and shape or adhesion in
primary B lymphocytes [157]. Further, EBV infection in alveolar epithelial cells caused the upregulation of the TGF-β1 pathway resulting in the inhibition of cell proliferation and the increase
of caspase 3 and 7 activities [158]. In addition, EBV infection influenced the modulation of DEK,
cyclin-dependent kinase (CDK) inhibitor, p53/retinoblastoma (RB) and cascades pathway
associated with E2F, activator protein 1 (AP-1), nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-kB) and STAT in nasopharyngeal carcinoma (NPC) transformation [159].
Microarray assay on hCMV infected human monocyte showed the alteration of host cellular
functions such as a unique M1/M2 polarization leading to develop the classical M1 activation
phenotype [160].

3.3. Bioinformatics
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Bioinformatics has been highlighted as a new approach to manage massive amounts of
data from advanced technologies such as microarray or high-throughput DNA sequencing
technology. Consequently, the priority of bioinformatics has been to analyze experimental data,
to find a prime candidate to predict results and to aid research projects. More powerful and
comprehensive analysis program or tools has been required to manage rapid and accurate data
analysis [161].
Normally, bioinformatics tools have been categorized into several groups such as
homology and similarity analysis, protein function and structure analysis, genomic sequence
analysis. The homology and similarity analysis is conducted to identify the evolutionary
relationship and divergence of genes among different samples [162]. Protein function analysis is
to determine critical motifs and domains, and the secondary structures of predicted protein
sequence compared to previous information in databases [163, 164]. The protein structure
analysis illustrates a protein's 2D or 3D structures which are essential for the functional study.
Genomic sequence analysis programs determine a query sequence thoroughly to identify mutated
sequences or regions, evolutionary analysis and compositional bias [165, 166].

3.4. Bioinformatics Tools
The basic local alignment search tool (BLAST; http://blast.ncbi.nlm.nih.gov/Blast.cgi)
provided from National Center for Biotechnology Information (NCBI) is widely used for
comparing gene and protein sequences. To date, several types of BLAST including nucleotide
BLAST, protein BLAST, BLASTx, tBLASTn and tBLASTx are available on NCBI website. In
NCBI, specialized tools are also available for primer selection, finding conserved domains, gene
expression omnibus (GEO), immunoglobulins (igBLAST), transcript and genomic libraries
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based on human, animal, plant, microorganism and other genomes. FASTA, which was first
introduced by Pearson and Lipman in 1988 using the rapid sequence algorithm [167], have been
widely used to search similarity of sequences of either nucleotides or peptides. The European
Molecular Biology Open Software Suite (EMBOSS), which is a free open source software for
the molecular biology and bioinformatics users [168], contains numerous programs for sequence
alignment, codon usage analysis, CpG island detection and analysis, database searching with
sequence patterns, protein motif identification and domain analysis, and protein analysis and
more. ClustalW is intended for multiple sequence alignment of DNA or proteins
(http://www.clustal.org/). Biologically meaningful sequences or divergent sequences are
determined through the best match of the selected sequences. RasMol is a powerful computer
program displaying the structure of DNA, proteins and smaller molecules [169].
The Database for Annotation, Visualization and Integrated Discovery (DAVID;
http://david.abcc.ncifcrf.gov/) has been widely used for functional annotation and gene
functionality to grasp the meaning of huge number of genes identified by functional genomics
data. Using DAVID, gene ontology (GO) terms, functionally related genes and groups, and
protein functional domains and motifs can be identified. Moreover, gene pathway maps and
related many genes and terms on 2D view can be visualized.
A newly developed program, ingenuity pathway analysis (IPA;
http://www.ingenuity.com/products/pathways_analysis.html) program, helps to understand the
complex, dynamic interaction between targeted molecules and surrounding molecules in life
science research. To date, IPA has broadly supported various species such as plant, bovine, C.
elegans, canine, zebrafish, fruit fly, chicken, Rhesus Monkey, chimpanzee and yeast as well as
thousands of peer-reviewed journal articles. IPA provides integrated information and insight into
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the biological and chemical interactions at various ways with different experimental platforms
such as microarray and next-generation sequencing based on the programs own knowledge base
system.

4. Host responses against the infection of herpesvirus family
4.1. Host responses by HSV-1 infection
ILTV genes and genome organization are highly conserved compared to those of HSV-1
indicating close and potential evolutionary relationship between HSV-1 and ILTV [111, 170].
Recently, HSV-1 infection and host responses have been studied using various methods such as
microarray [153, 171-174] and qPCR [175-178], and various conditions such as in vitro [179183] and in vivo [184-186]. The microarray results of the infection of various viruses including
HSV-1 provided insights into host virus interactions and further, knowledge obtained from these
assays can be compared to systems against infections of other herpesviruses such as ILTV.
HSV-1 infection in neuronally differentiated PC12 cells up-regulated host genes related
to proteolytic enzymes for neurite outgrowth/axon remodeling, while the DNA and nucleotide
metabolism and apoptosis related host genes were down-regulated suggesting that HSV-1
infection in neuronal cells led to accelerate cell survival and maintain latent infection [187]. In
other study, HSV-1 infection leads to the modulation of leukocyte trafficking to inflamed tissues
by chemokines, which critically organize the immune response in host cells [188].
In HSV-1 infected cells of the human neuronal cell line, early growth response 1 (EGR1) is up-regulated, and EGR-1 reduces the HSV-1 LAT gene expression by blocking the
immediate downstream site of the TATA box [189, 190]. Furthermore, the mortality of mice was
reduced by the depression of EGR-1 expression [191]. In rabbit corneal cells, EGR-1 is rapidly
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induced by NF-κB and CREB mediated transactivation by HSV-1 infection [180]. In the mature
dendritic cells, tumor necrosis factor (TNF) mRNA is destabilized by the induction of the AUrich elements (ARE)-binding protein tristetraprolin (TTP) in both the STAT1 and p38-dependent
manners [192], and the expression of large multifunctional peptidase 7 (LMP7) mRNA is downregulated [193]. The expression of chemokine (C-X-C motif) ligand 9 (CXCL9) stimulated by
TNF-α and IFN in HSV-1 infected brain is dependent on either TLR2 or TLR9 to induce innate
antiviral responses [194]. The recognition of HSV-1 by innate immunity in dendritic cells is
occurred in glycoprotein-dependent and TLR2-independent manners [195]. Human leukocyte
antigen (HLA)-G which is a nonclassical human major histocompatibility complex class I
(MHC-I) and functions in anti-inflammatory responses are up-regulated by HSV-1 infection in
human neuroblastoma cells, SK-N-SH and human neurons, NT2-N [196, 197]. Caspase 3 and 7
are activated by HSV-1 infection, and these proteins contribute to HSV-1-dependent apoptosis
[198]. Galectin-1 (Gal-1), which is an endogenous lectin functioning in T-cell apoptosis, is upregulated by HSV-1 infection to avoid from the activation of host immune system by removing
activated T-cells [199]. In HSV-1 infection, interferon regulatory factor (IRF), IFN, IL15 and
natural killer (NK) cells critically function in host innate immunity according to in vivo study
[200]. The data and knowledge on HSV-1-host interaction obtained from microarray studies for
HSV-1 could provide the basis on understanding of ILTV-host interaction and host defense
mechanisms in ILTV infection for this dissertation.

4.2. The function of HSV-1 viral genes in host responses
Due to the high genetic and functional conservation between ILTV and HSV-1, the
analogical interpretation of the function of ILTV genes can be predicted from previously known
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HSV-1 studies. ICP0 protein is expressed in the immediate early stage of HSV-1 infection and
promotes the transcription of both viral and cellular genes [201]. During lytic infection, ICP0
acts as an IFN antagonist to block a STAT1-dependent host response involving innate immunity
[202], supresses the expression of SIAH-1, a cellular E3 ubiquitin ligase [203] and deactivates
NF-κB and c-JUN N-terminal kinase (JNK) which are the downstream effectors of the TLR
signaling pathways [204]. In addition, HSV-1 US7 helps the block of the TLR-mediated NF-κB
and JNK through the deubiquitination of TRAF6 and IKK-γ [204]. US3 encoding
serine/threonine kinase controls the neuronal apoptosis of peripheral nervous region to prevent
from virus transmission to the CNS [205].
ICP27 suppresses host gene transcription in addition to cell cycle arrest at the G1 phase
and apoptosis [206, 207]. ICP27 is the counterpart to induce the early innate immunity by
activating type 1 IFNs (IFN-α and β), type III IFNs (IL28 and IL29), TNF-α, CC chemokines
ligand (CCL) 5 and CXCL10, and cytokines in macrophages and dendritic cells [208]. ICP27 has
critical roles to inhibit STAT/Janus kinase (Jak) pathway by phosphorylation of STAT-1 [209],
the secretion of type I interferon-antagonizing protein and IFN signaling by Jak-1 activation
[210]. Moreover, ICP27 is related to both a extracellular signal-regulated kinase (ERK)
activation and ERK survival activity by producing the AU-rich instability elements (AREs)containing IEX-1 which is a extracellular signal-regulated kinase (ERK) substrate [211] and is
also associated with the stability of the AREs-containing IEX-1 mRNA through the activation of
p38 mitogen-activated protein (MAP) kinase (MAPK) pathway [212, 213].
ICP34.5 is associated with viral maturation and egress [214] and acts as a neurovirulence
factor for virus growth in the CNS tissue to maintain an appropriate condition for virus
replication [215]. Beclin-binding domain (BBD) of ICP34.5 interacts with Beclin 1 (Atg6) to
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regulate HSV-1 pathogenesis by the modulation of CD4+ T-cell responses [216]. The regulation
is controlled by interferon regulatory factor (IRF) 3-dependent pathways in cells of the nervous
system [217, 218]. ICP34.5 plays a role in the evasion of the host immune system by the
dephosphorylation of eukaryotic initiation factor (eIF) 2α in the cytoplasm [219].

4.3. Host responses by MDV
Marek’s disease virus (MDV) serotype 1 is the avian alphaherpesviruses known as Gallid
herpesvirus 2 (GaHV-2) causing viral T cell lymphoma in chickens [220]. MDV-1 has been
studied intensively due to the fact that MDV is an oncogenic herpesvirus in cells of the host’s
immune system. Particularly, the immune responses and viral gene expression during MDV
infection have been studied by the microarray analysis [156, 221-223]. The infection of highly
oncogenic MDV RB1B strain in the bursa of Fabricius of chickens significantly up-regulates
thioredoxin domain-containing protein 5 (TXNDC5), Ras-related protein Rab11A and budding
uninhibited by benzimidazoles 3 homolog (BUB3) at 14 and 21 dpi, and IFN-α, IFN-γ, inducible
nitric oxide synthase (iNOS) and CD4+ T cells at 4 to 14 days [224, 225]. The up-regulated
genes produce tumor-associated proteins functioning in cell metabolism, immune and stress
responses, apoptosis and tumorigenesis. In addition, in MDV RB1B strain infection of CEF,
MHC class I is significantly decreased, while IFN expression is increased to prevent MHC IImediated antigen presentation [226, 227]. In contrast, MDV Md11 strain, which is very virulent
serotype 1, enhances MHC class II cell surface expressions in CEF cells [228].

4.4. The function of MDV viral genes in host responses
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ILTV could be an evolutional ancient of MDV and HVT. Thus, it suggests that the
function of MDV genes may help understand ILTV gene expression comparing to the HSV-1
gene study. The MDV pp38 protein encoded by LORF12 and its splice variants may function in
metabolic activity resulting in latency and tumor development [229]. Moreover, the pp38 protein
was involved in MDV reactivation [230]. The Meq homodimer, MDV nuclear oncoprotein, is
essential to transform T-cell lymphoma by the interplay with c-Jun [231]. The plenty of MDV
Δmeq lacking domains of the basic leucine zipper (bZIP) and transactivation domains are found
in MDV infected cells during apoptosis, while L-meq was highly expessed in MD-derived
lymphoblastoid cell lines [232]. Thus, in MDV infected cells, L-meq functions in anti-apoptotic
effects, and Δmeq acts as a negative regulator in apoptosis.

4.5. Host responses in HVT infection
In HVT infected CEF cells, the expression of 56 cellular genes involving IFN, signal
transduction, transcription, scaffolding proteins and cytoskeleton related proteins are altered
[151]. The vnr-13 protein encoded HVT shows 80% homology with cellular Nr-13 which
belongs to Bcl-2 family, is an apoptotic inhibitor, and functions to prevent apoptosis and to
reduce cellular proliferation [233, 234].

5. Control of ILTV outbreak
5.1. ILTV vaccines
Commercial attenuated live vaccines have been used to prevent chicken flocks from
ILTV outbreaks for many years [42]. Vaccinal laryngotracheitis (VLT) which was caused by the
reversion of ILTV vaccine virulence is a current serious issue for the global poultry production.
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To overcome this problem, inactivated vaccines and subunit vaccines using a HVT vector
containing ILTV glycoproteins such as gI and gD or fowlpox-vectored infectious
laryngotracheitis (FP-LT) vaccine have been developed and successfully tested [235, 236].
However, the high production costs and labor intensive immunization method of those
approaches have been limited to use in large flocks. Therefore, the development of new vaccines
such as genetically engineered live vaccines against ILTV has been demanded continuously.
To find a genetically engineered vaccine candidate, 14 ILTV genes including UL0, ORFA to E, UL10, UL21, UL23, UL47, UL49.5, UL50, US4 and US5 were tested by individual
removal from the ILTV genome. Individual deletions of ILTV genes listed above did not
influence to ILTV propagation in cultured cells, indicating those genes are not necessary for
virus replication. In turn, ILTV deletion mutants have been tested in vivo animal system as live
virus vaccine candidates [44]. The deletion mutants of UL23 (TK gene), US4 (gG), UL47
(tegument protein), US5 (gJ) and UL0 (nuclear protein) completely decreased the virulence of
ΔILTV [83, 130, 237-239]. UL50 (dUTPase) deletion mutants might be applied in low doses
though the high doses of the mutant caused significant virulence in terms of intratracheal
infection [81]. The gJ and possibly gG deleted mutants would serve as marker vaccines for the
differentiation of infected from vaccinated animals such as DIVA strategy [238, 240]. These
results suggest that a genetically engineered ILTV strain might substitute for current vaccines to
a new vaccine candidate.

The objectives of this dissertation research are: 1) host responses against virulent ILTV
infection in primary chicken embryo lung cells using microarray assay; 2) host responses against
vaccine ILTV infection in primary chicken embryo lung cells using microarray assay; and 3)
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expression analysis of whole ILTV encoding genes at different time points using quantitative
PCR technique.
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1. Abstract
Infection of infectious laryngotracheitis virus (ILTV; gallid herpesvirus 1) causes acute
respiratory diseases in chickens, resulting in a high mortality rate. To better understand hostILTV interactions at the host transcriptional level, a microarray analysis was performed using 4
X 44K Agilent chicken custom oligo microarrays. Microarrays were hybridized by using the two
color hybridization method with total RNA extracted from ILTV infected chicken embryo lung
cells at 0, 1, 3, 5, and 7 days post infection (dpi). Results showed that 789 genes were highly
altered in their expression during the time courses of ILTV infection. The differential
expressions include genes responsible for immune responses (cytokines, chemokines, MHC, and
NF-kB), cell cycle regulation (cyclin B2, CDK1, and CKI3), matrix metalloproteinases (MMPs)
and cellular metabolism. Differential expressions for 20 out of 789 genes were confirmed by
quantitative reverse transcription-PCR (qRT-PCR). A bioinformatics tool (Ingenuity Pathway
Analysis) was used to analyze biological functions and pathways on the group of 789 genes that
exhibited highly altered expression, resulting in that 275 genes were classified into a number of
functional groups including cancer, genetic disorder, cellular growth and proliferation, and cell
death. Furthermore, 21 possible gene networks indicating the intermolecular connections among
275 functionally identified genes were generated using the gene network analysis. Results
provide comprehensive knowledge on global gene expressions, and biological functionalities on
differentially expressed genes in the host responses to ILTV infections.
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2. Introduction
Infectious laryngotracheitis virus (ILTV; gallid herpesvirus 1) is the only member of the
Iltovirus genus of the Alphaherpesvirinae subfamily of the Herpesviridae family. ILTV includes
~150 kb of linear dsDNA genome consisting of two unique regions (unique long; UL and unique
short; US), inverted repeats (IR) and terminal repeats (TR) flanking the US region [15]. About
76 open reading frames (ORFs) have been shown to express viral proteins [53]. The genome
structure and gene contents of the ILTV genome clearly proved its classification as an
alphaherpesvirus [45]. Infection of ILTV causes upper respiratory diseases in chickens during
lytic infection, and ILTV can establish latency in the central nervous system. ILTV infection
causes severe respiratory diseases such as increased mucus formation in the trachea and tracheal
hemorrhage. In acute cases, there has been up to 70% mortality in infected chickens. Currently,
live attenuated vaccines, which are developed from chicken embryo or cultured cells, are
commercially available to control ILT disease [3]. However, vaccinal laryngtracheitis (VLT),
which is caused by the reversion of vaccine virus to virulence by spreading from vaccinated- to
unvaccinated birds, is critically associated with live attenuated ILTV vaccines [8, 19].
Microarray methodology was developed as an epochal method to simultaneously analyze
enormous data sets for gene expression patterns in various biological conditions [28].
Microarrays have been used to investigate host responses to the infection of various viruses such
as Epstein-Barr virus (EBV) [5, 7, 36], varicella-zoster virus (VZV) [25], human
cytomegalovirus (HCMV) [6], Marek’s disease virus (MDV) [21, 33, 38, 46, 47], herpesvirus of
turkey [26], herpes simplex virus-1 (HSV-1) [9, 40], hepatitis virus [41], human
immunodeficiency virus (HIV) [10, 16, 50, 54] and coxsackieviruses [52].
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ILTV, which is a special type of herpesvirus causing acute respiratory diseases, has not
been studied sufficiently in genetic phases of host-virus interactions. Thus, the objective of this
study was to understand host responses to ILTV infection in cultured chicken embryo lung cells
using microarray analysis. The microarray used in the current study contains 44K chicken genes
including functionally identified genes, predicted ORFs, ESTs, genomic contigs, chicken
microRNAs and various control spots [32]. Genes were sorted into three groups according to the
level of alterations at four different days post infection (dpi) time points. The 20 genes showing
the great alterations during the time course of ILTV infection were validated by qRT-PCR.
Microarray data sets for genes expressed differentially can be interpreted further by
clustering analysis. Many of the heuristic clustering methods have several shortcomings,
including the determination of the number of clusters which generally is unknown when there is
no prior knowledge of the number or there no other information about the structure of the data to
be clustered. A model-based clustering method can overcome the critical drawback by estimating
the number of clusters in clustering analysis, treating a clustering problem as a model selection
problem over a variety of candidate models specified by different numbers of clusters and
distribution. The best model is selected on the basis of a model selection criterion, providing the
optimal number of clusters and assigning cluster membership to observations simultaneously.
Importantly, the functional analysis of differentially expressed genes should be followed
by gene discovery research. However, it is difficult to find which gene (or set of genes) is a core
regulatory factor or how genes interact with each other in a specific biological mechanism. The
Ingenuity Pathway Analysis (IPA) program was developed to analyze large data sets such as
microarray data in biological functionalities, gene networks, and physiological pathways [37].
Differentially expressed genes obtained from the microarray analysis of chicken lung cells
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infected by ILTV were analyzed by using IPA program to find biological functionalities and
molecular interactions.
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3. Results and discussion
3.1. Gene expression profile of lung cells infected by ILTV
Primary chicken embryo lung cells at passage 1 were infected by the USDA reference
strain of ILTV and cells were collected at 1, 3, 5, and 7 dpi. Cytopathic effects (CPE) were
observed from 3 dpi, which became more severe by 5 dpi, and finally massive cell disruption
observed at 7 dpi (Figure 1). Total RNA was isolated from both controls and infected lung cells
at each dpi time point and subjected to microarray analysis.
To control dye bias effect, spike-in control mixtures were utilized by mixing with RNA
samples according to manufacturer’s recommendations, and in the recommend quantity
(Methods). The spike-in RNA controls consist of two sets of synthetic RNA mixtures derived
from the Adenovirus E1A genes with different concentrations in each set [55]. Agilent chicken
4X44K oligo gene expression array contains 320 spike-in indicating spots to be hybridized with
spike-in controls of both A mix, which was hybridized with Cy3, and the B mix hybridized with
Cy5 on each array. These spike-in sets were mixed with either uninfected control or infected
samples and co-hybridized to arrays. The ratio of signal intensities for all spike-in spots were
calculated and evaluated, resulting in that no significant dye effects were detected for all array
slides (data not shown) as reported previously [55]. All raw and normalized data were deposited
to Gene Expression Omnibus (GEO) and the accession number is GSE20630.
Normalized signal intensities were subjected to statistical analysis to find differentially
expressed genes during ILTV infection in cultured lung cells. The 44K array produced 11,491
genes that showed significant signal intensities that were sorted by signal to noise ratio (SNR) >3,
meaning that real (forward) signals of the samples were three times greater than background
signals. In order to discover the expression patterns over time in the data, a model-based
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clustering method [14] is used for clustering the gene expression profiles. A key drawback in
heuristic clustering techniques is that they are difficult a priori to determine the number of
clusters. The method enables the number of clusters to be determined by estimating the number
of components in a multivariate normal mixture model from which the data are generated. The
clustering analysis results in three clusters, and Figure 2 presents these clusters. 789 genes
showed significant differential fold changes in response to ILTV (Group 1), 6,265 genes
displayed moderate alterations (Group 2), and 4,437 genes revealed no alterations during ILTV
infection at four time points in chicken lung cells (Group 3). Of the 789 genes in Group 1
exhibiting considerable changes in differential expression in response to ILTV (see supplemental
Table 1), the top 10 % (79 genes) were sorted by statistical analysis based on the highest value of
standard deviations from the mean values of four different time points (Table 1). This is for the
purpose to gain insights into genes with more significant alterations during the time course. Out
of the 789 genes, 390, 370, 320, and 422 genes were down-regulated, while 399, 419, 469, and
367 genes were up-regulated at 1, 3, 5, and 7 dpi, respectively.

3.2. Quantitative reverse transcription-PCR (qRT-PCR)
To validate the microarray data, 20 of 789 genes were subjected to qRT-PCR with the
same RNA samples used in the microarray analysis using gene specific primer pairs (Table 2).
Results were analyzed by 2-∆∆Ct method to determine relative levels of gene expression at each
dpi time points compared to uninfected control [34]. There were no differences found between
data of microarray or qRT-PCR at any dpi time point (Table 3). However, it should be noted that
fold change values for certain genes obtained by qRT-PCR analysis showed much greater
expression levels than those observed in the microarray analysis. For example, fold changes for
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gene expression for matrix metalloproteinase (MMP) 27, interleukin (IL) 6, fatty acid binding
protein (FABP) 4, IL8, and CXC chemokine K60 at 3- or 5 dpi showed much higher levels in
qRT-PCR analysis compared to fold changes shown in microarray analysis. This qualitative
difference between methodologies may be attributed to the upper detection limits of the
fluorescent intensities for the array scanner.
Both quality control data taken with spike-in controls and the results of qRT-PCR
indicate that the microarray data sets for differential gene expression are valid to investigate
genome-wide differential expression patterns for host responses during ILTV infection.

3.3. Expression clustering
The pattern of differential gene expression over time can provide insights into
biologically functional relevance among genes. In the present study, a model-based clustering
method [14] was used to cluster alteration patterns for the 789 differentially expressed genes in
response to ILTV infection and revealed 7 gene clusters exhibiting distinct expression patterns
(Figure 3 and supplemental Table 2). The 287 genes placed in cluster (C) 1 showed only nominal
increases at 3 and 5 dpi followed by decreased expression levels at 7 dpi that were similar to
those at the onset of the experiment . The C2 representing 97 genes exhibited a dramatic increase
in gene expression only at 7 dpi, whereas the expression levels of the 90 genes in C3
progressively declined at 5 and 7 dpi. Three genes in C4 showed higher levels of expression
from the early infection stage (1 dpi), sharp increases at 3 and 5 dpi, and slight declines at 7 dpi.
Expression patterns of 9 genes in C5 showed slightly lower expression at 1 dpi relative to the
other time points, and then dramatically increased in 3 and 5 dpi, followed by decreased
expression at 7dpi. The 85 genes in C6 showed lower levels of expression in 1 dpi and then
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expression was progressively increased during the later time points, whereas C7 representing 218
genes showed higher expression levels in the 1 dpi and progressively decreasing at 3, 5, and 7
dpi. GenBank accession numbers for genes in each cluster are shown in supplemental Table 2.
Interestingly, the genes in C4 that exhibited the highest expression during ILTV infection
include cytokines (IL8 and IL1-beta) and a chemokine (CXC-K60), while in the C5, IL6 showed
the most highly expressed. From these findings, it is reasonable to hypothesize that expression of
functionally relevant genes such as cytokines and chemokines released in response to an immune
challenge may be regulated similarly during a specific biological condition.

3.4. Functional clustering
Recently, new bioinformatics tools have been developed to facilitate efficient analyzing
for biological functionalities for large number of differentially expressed gene sets obtained from
microarray analysis. By using the IPA program (http://www.ingenuity.com/), bioinformatics
aspects of differentially expressed genes during ILTV infection were analyzed for the relevance
of gene functionalities and gene networks. Since gene functionalities and network analyses used
in IPA program are based on the genetic information of mammalian species including human,
mouse, and rat, data drawn from the chicken microarray were analyzed depending on
mammalian biological pathways. In this study, whereas 789 differentially expressed genes were
used as the input number of genes, only 275 have been characterized with specific cellular
functions. Also, other bioinformatics tool, Database for Annotation, Visualization and Integrated
Discovery (DAVID) version 6.7 (http://david.abcc.ncifcrf.gov/), was utilized to identify gene
functionalities, resulting in that the similar number of genes were identified for their biological
functions to the data obtained with IPA program (data not shown). Furthermore, the biologically

56

functional categories for gene information are also similar to those of IPA analysis (data not
shown). Thus, the following bioinformatics results are based on the group of 275 genes obtained
from the IPA program.
The group of 275 differentially expressed genes were clustered as to 65 functional groups
(see supplemental Table 3) and the top 25 functional groups of genes are displayed in Figure 4.
The main categories for gene functionalities include diseases and disorders, molecular and
cellular functions, and physiological system developments. Gene information was repeatedly
used in multiple clusters of functionalities due to the multi-functional characteristics for
designated genes. It can be seen that the cancer related function contains the highest number (140)
of genes, while 125 genes were involved in genetic disorders, and 54 genes were clustered as
inflammatory responses.

3.5. Gene network analysis
In addition to functional clustering analysis, gene network analysis was performed using
the IPA program, resulting in that top 6 network groups were generated from differentially
expressed genes (supplemental Table 4). The network analysis represents the intermolecular
connections among interacting genes based on the functional knowledge inputs contained within
the IPA program. Independent networks were generated in each dpi sample group with
considering alteration levels of expression, and 21 possible gene networks for all dpi groups
were obtained from the 275 functional input genes. Of the 21 potential gene networks, only top 6
identical networks were observed across all dpi time points. It might be caused by different sets
of focus molecules, which were generated based on different p-values calculated by the IPA
algorithms with the altered fold change values in each dpi group. Dynamics of alterations in gene
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expression for a subset of genes during the time course of ILTV infection can provide insights
into biologically interacting genes within a network displaying functional similarities. The most
strongly interactive network (network #1) is presented in Figure 5 whereas the other networks
are shown in S1 in the supplemental materials.
The network #1 is closely associated with a signaling pathway of IL6, which is a cytokine
known to be involved in cell proliferation and inflammatory responses [27]. The top functions
related with genes in network #1 involve cancer, gastrointestinal disease, and the cell cycle.
Interestingly, expression of certain genes in network #1 such as CDC20 (cell division cycle 20
homolog), PTTG1 (pituitary tumor transforming 1), CDC2, and Cyclin B, which function for
cellular proliferation by the cell cycle progression, appeared to be inversely regulated with the
time course response of IL6 expression to ILTV infection. When considered functionalities of
genes in network #1, the dynamics of alterations in gene expression over time during ILTV
infection suggests that ILTV infection elevates IL6 expression followed by the inhibition of
cellular proliferation. In contrast, expression patterns of HPGD (hydroxyprostaglandin
dehydrogenase 15-NAD), SOCS (suppressors of cytokine signaling), JAK (Janus kinase 1), and
NASP (nuclear autoantigenic sperm protein) exhibited expression patterns that were independent
to the IL6 expression pattern (Figure 5A, 5B and S1. A). The consistent downregulation of JAK,
which is known to enhance cellular proliferation through signal transducer and activator of
transcription (STAT) pathway that can be suppressed by IL6 signaling [22], supports the
repression of cellular proliferation by ILTV infection. The top functions of genes in network #2
are involved with cellular compromise, connective tissue disorders, and post-translational
modifications. Several heat shock proteins (HSP) were focused in this network (see S1. B). Heat
shock proteins, especially HSP70 family as molecular chaperones, are known to interact with
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viral early immediate genes in HSV-1 genomic DNA replication [31]. Interestingly, the
expression of several HSPs in the network #2 are decreased consistently except in the 7 dpi,
suggesting that lowered level of HSPs until 5 dpi may lead to production of erroneous structures
of ILTV virions, resulting in the low titers of ILTV in tissue culture, which barely exceed on
infectious unit per cell [15, 18]. Network #3 contains genes for growth factors and matrix
metalloproteinases (MMPs), and the genes have top functions associated with endocrine system
development and function, carbohydrate metabolism, and digestive system development and
function (see S1. C). Levels of expression for growth factors and MMPs are increased from 3dpi
and maintained higher levels until 7dpi. Infection of herpesviruses, such as HSV and HCMV,
lead to an increase of the expression of growth factors and MMPs for extracellular remodeling,
tissue invasion and angiogenesis [20, 35, 48]. Networks #4 and #5 contain genes of the cytokines
(IFN beta and IL1B), chemokines (CCL20 and CCL4), and NF-kB families (NF-kB and NFIB)
and the top functions involve organism injury and abnormalities, antigen presentation, cell
mediated immune responses, lipid metabolism, small molecule biochemistry, and molecular
transport (see S1. D and E). Finally, genes in network 6 contain IL1, NF-kB, and ID1 that
function in cardiac inflammation, cardiovascular disease and inflammatory response (see S1. F).
Interacting molecules found in networks #4, 5, and 6 are mostly focused on the host immune
responses against pathogenic inflammations.
The network analysis suggests that a large number of biological pathways, regulated by
various sets of genes, closely interact each other in host responsiveness during ILTV infection.
More detailed interactions among genes showing altered expression levels in each network are
currently under investigation to find unknown host-response mechanisms in addition to general
immunological reactions during ILTV infections.
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The altered fold changes for interesting molecules that were associated with cellular
immune response, cell signaling, MMP molecules, cytokines, chemokines, and cell proliferation
are plotted individually (Figure 6) since the those molecules are noteworthy on clarifying the
interaction of host lung cell and ILTV. Four matrix metalloproteinases (MMPs) including MMP
7, 13, 16, and 27 were differentially expressed during ILTV infections. Previously, MMP 1, 2,
and 9 were shown to function in cell invasions of primary human endothelial cell in Kaposi's
sarcoma-associated herpesvirus (KSHV) pathogenesis [42]. The viral oncoprotein meq in MDV
is known to activate MMP3 transcription [2]. Furthermore, in HCMV infection, the balance of
MMP9 and tissue inhibitor of metalloproteinases 1 (TIMP1) was changed in human
macrophages, and the MMP9 activity was declined in infected cells. It could be proven that
HCMV infection may affect atherogenesis in mice through the control of MMP9 expression. [48].
Taken together, these results suggest that MMPs generally play a role in herpesvirus
pathogenesis, but different isoforms of MMPs may be capable of responding to specific
herpesviruses. Furthermore, in the present study with chicken lung cells, expression of surfactant
protein A (SFTPA-1; GenBank accession - AF411083; Table 1 and 3) was downregulated by
ILTV infection. When considering that surfactant protein A is a transcriptional indicator of
EGFR (epidermal growth hormone receptor) signaling pathway [11], EGFR signaling pathway
was suppressed during ILTV infections. This result is consistent with the downregultion of
EGFR functions in hCMV infected human lung [11] and foreskin fibroblastic cells [23]. Also,
our result is same as the mRNA expression of SFTPA-1 that was decreased after inoculation of
influenza A virus H9N2 into chicken lung cells [44]. Ovotransferrin (Otrf; GenBank accessionX02009; Table 1 and 3) is related with both iron transport and antibacterial activities. In the
present study, the expression level of Otrf was increased in ILTV infected cells (Figure 6A). The
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finding may lead to similar results that the upregulation of Otrf in MDV infection could protect
the spread of MDV in chicken embryonic fibroblast [17]. Otrf accelerates the expression of
immune response gene such as IFN-γ against MDV infection [12]. Futhermore, lactoferrin which
is homologous form of transferrin in mammals showed antiviral activity against canine
herpesvirus [51]. It has been hypothesized that the anti-viral activity of Otrf may be similar to the
anti-HSV capability of mammalian transferrins [24]. IL6 plays a role in both pro-inflammatory
and anti-inflammatory responses [27]. The elevation of IL6 expression during virus infection is
one of well-characterized immune responses in the pathogenesis of various viruses, such as
Dengue virus in human [30], or HSV-1 in mice [29]. Also, the expression of IL6 is increased by
KHSV-encoding miRNA [43]. Similarly, expressions of IL8 and IL1B were upregulated in ILTV
infected cells, and gene expression pattern were observed in MDV infected chicken lung [1].
These are consistent with previous findings of NF-kB activation via IL8 signaling pathway by
human herpesvirus (HHV)-8 infection [49] and HHV-6 infection in peripheral blood
mononuclear cell cultures [13], respectively.
In addition to the well-characterized host-virus interactions, a variety of unique responses
were drawn from the microarray analysis of ILTV infection. For instance, the expression level of
vasoactive intestinal peptide (VIP; GenBank accession number- U09350: Table 1 and 3) was
decreased dramatically in ILTV infection, but the functional aspects were not determined.
Likewise, genes related to various metabolic enzyme functions such as acyl-CoA synthetase long
chain-1 (ACSL1; GenBank Accession number- AJ851480; Table 1 and 3) were differentially
expressed in ILTV infected cells, but the precise mechanisms have not been verified. Therefore,
further investigations are being performed to identify unique and more deeply involved
interactions between host and ILTV.
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4. Materials and methods
4.1. Cell culture and ILTV infection
Cell culture reagents were purchased from Invitrogen Life Technologies (Carlsbad, CA,
USA). Chicken embryo lungs were isolated from 19 day old specific-pathogen free (SPF)
chicken embryos (Charles River Laboratories, North Franklin, CT, USA). Lung tissues were
homogenized and incubated in a 0.125% trypsin solution for 30 min at room temperature (25°C).
Cells dissociated from lung tissues were suspended in a 1:1 ratio of mammary epithelial growth
media (MEGM; Lonza, Rockland, ME, USA) and Dulbecco’s Modified Eagle’s Medium
(DMEM, 0.45% glucose) plus 2% fetal bovine serum (FBS), 100units/ml penicillin, 100µg/ml
streptomycin, and 2mM L-glutamine in 10 cm tissue culture dishes (Sarstedt Inc., Newton, NC,
USA) pretreated with 0.5% gelatin in PBS to improve cell adhesion. Cultured cells were grown
at 39°C containing 5% CO2 until cells reached confluent monolayers (2 to 4 days). The USDA
reference strain of ILTV (National Veterinary Services Laboratories, Ames, IA, USA) was used
to infect the chicken embryonic lung cells at a multiplicity of infection (m.o.i.) of 0.1. Infected
cells were incubated at 37°C for 1hr with rocking gently every 15 min. After the incubation,
10ml of media, 1:1 MEGM/DMEM, were added to each culture dish, and the cells were
incubated at 37°C in 5% CO2 for up to 7 days. This research was performed under the permitted
protocol approved by both the Institutional Biosafety Committee (IBC; permit number: 10007)
of University of Arkansas and the Animal and Plant Health Inspection Service (APHIS; permit
number: 102743) of United States Department of Agriculture (USDA).

4.2. Total RNA extraction
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Total RNA was extracted from uninfected- or ILTV infected chicken embryonic lung
cells at 1, 3, 5, and 7 dpi using TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA,
USA) following the manufacturer’s instructions. Total RNA was treated with DNase I (New
England BioLabs Inc., Ipswich, MA, USA), and RNA was re-purified by the TRIzol reagent.
The quality of RNA was checked by fractionation on an agarose gel (data not shown).

4.3. Probe labeling and microarray hybridization
A two color labeling microarray system was used to compare uninfected- and ILTV
infected embryonic lung cells at 1, 3, 5, and 7 dpi. Fluorescently labeled complementary RNA
(cRNA) probes were generated by using the Two Color Microarray Quick Labeling kit (Agilent
Technologies, Palo Alto, CA, USA) and following the manufacturer’s instructions. RNA spikein controls were used to adjust possible dye effects following manufacturer's instructions. The
Spike-in controls represent two sets of ten synthesized RNA mixtures derived from the
Adenovirus E1A transcriptome with different concentrations in each set [55]. These spike-in sets
were mixed with either uninfected control or infected samples and co-hybridized to arrays.
Briefly, 2 g of total RNA were mixed with Spike-ins and converted to cDNA using reverse
transcriptase and oligo dT primers in which T7 promoter sequences were added. T7 RNA
polymerase was used for the synthesis and labeling of cRNA with either Cy3 dye for the
uninfected control or Cy5 dye for the ILTV infected samples. The fluorescently labeled cRNA
probes were purified using the Qiagen RNeasy Mini Kit (Qiagen Inc., Valencia, CA, USA), and
the concentration, fluorescent intensities, and quality of labeled cRNA probes were determined
using a Nano-drop spectrophotometer (Thermo Scientific, Wilmington, DE, USA). An equal
amount (825ng) of Cy3 and Cy5 labeled cRNA probes were hybridized on a 4X44K Agilent
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custom chicken oligo microarray (array ID: 017698). The hybridized slides were washed using a
commercial kit package (Agilent Technologies, Palo Alto, CA, USA) and then scanned using a
Genepix 4000B scanner (Molecular Devices Corporation, Sunnyvale, CA, USA) with the
tolerance of saturation setting of 0.005%. Three biological replicates were conducted.

4.4. Microarray data collection and analysis
Background-corrected red and green intensities for each spot were used in the subsequent
analysis. Global normalization based on local polynomial regression (loess) was applied to the
intensities to remove effects that were due to undesirable systematic variations in microarray
experiments rather than biological differences. The average values of the resulting normalized
expression values in replicate hybridization sets were considered in the subsequent analysis. In
order to identify a set of genes with high alterations over time, a model-based clustering method
[14] was employed, and the genes in the cluster were considered as differentially expressed over
the time period. All analytic techniques were implemented in R (http://www.R-project.org).

4.5. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)
Reverse transcription was performed with 3 μg of total RNA using Superscript II reverse
transcriptase (Invitrogen Life Technologies, Carlsbad, CA, USA) with oligo dT12-18 primers
(Invitrogen Life Technologies, Carlsbad, CA, USA) following the manufacturer’s instructions.
The reverse-transcribed products were diluted by 1:10 ratio and a portion (1

l) of each product

was subjected to qPCR under the following conditions: 40 cycles of 95°C for 30 s, gene-specific
annealing temperature for 62°C for 1 min, extension for 30 s at 72°C, and a final extension at
72°C for 10 min. A non-template control and endogenous control (chicken GAPDH) were used
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for the relative quantification. The differential expression levels for the ILTV infected group
were compared by the 2-ΔΔCT method against the uninfected controls [34]. Primers for qRT-PCR
were designed using Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3.cgi) with
these parameters: amplicon length, 95–100 bp; primer length, 18–27 nucleotides; primer melting
temperature, 60–64°C; primer and amplicon GC content, 20–80%; difference in melting
temperature between forward and reverse primers, 1–2°C. Primers were synthesized by
Integrated DNA Technologies (Coralville, IA, USA). Primer information is listed in Table 2.

4.6. Bioinformatics
Functional interpretation of differentially expressed genes was analyzed in the context of
gene ontology and molecular networks using the Ingenuity Pathways Analysis (IPA) 6.5
software (Ingenuity Systems®; www.ingenity.com). The differentially expressed genes were
categorized, compared to genetic categories in the IPA database, and ranked according to pvalues. [39]. The IPA analysis determined the subcategories within each category which is
supplied with an appropriate p-value and the number of genes identified. Since the size of the
created network could potentially be enormous, the IPA software limited the number of
molecules in the network to 35, leaving only the most important ones based on the number of
connections for each focus gene (focus genes= a subset of uploaded significant genes having
direct interactions with other genes in the database) to other significant genes [4].
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Table 1. Top 10% (79 out of 789 genes) of the most highly differentially expressed.
Accession #

Gene Symbol

Y14971
X65459
X16881
X03509
X02009
U62026
U12438
U09350
M16199
CR733296
CR523746
CR406543

CXC chemokine K60
FABP7
CDC2
CKB
LTF
CENPF
RFC2
VIP
IL8
LIPG
TMEM196
SELO
Prematurely terminated mRNA
decay factor-like
ITGA8
LL
CHAD
IDl1
MYCN
DHCR7
HDGFRP3
OSTN
HSP90AA1
ARHGEF9
ALDH1A3
FDPS
AURKA
XBP1
AKR1D1
MAT1A
TFPI2
PTTG1
SPON2
ROPN1L
SNAl1
HMG_COA_S
TNFAIP6
CYP51
ACSL1
VNN2
SLA
LSS
DNAJB9
STARD4

CR406252
CR391404
CR391234
CR387914
CR385491
CR385166
CR385124
CR382435
CR352395
CO635775
CN218923.1
CF250950
CD763113
BX936026
BX935864
BX935550
BX935026
BX934121
BX932212
BX931971
BX931663
BU456021
BU409770
BU200000
BU138507
AJ851480
AJ721110
AJ721107
AJ720861
AJ720657
AJ720217

Fold Change
Day 3
Day 5

Day 7

3.7
1.1
1.9
0.9
0.7
3.3
1.9
2.0
3.7
1.0
1.0
1.0

17.3
0.3
0.4
4.7
2.7
0.7
0.8
0.2
22.4
0.7
2.3
0.9

19.7
0.8
0.7
5.5
3.6
1.4
1.0
0.3
26.8
0.6
2.8
1.1

11.3
0.2
0.4
2.0
3.2
0.6
0.3
0.2
18.5
0.1
0.7
4.1

1.2

1.1

1.4

4.7

0.7
1.5
1.1
1.3
0.6
1.3
0.8
0.8
0.8
1.1
0.6
1.1
2.4
0.9
0.6
0.7
0.9
2.1
1.6
0.7
1.9
2.5
1.0
1.0
1.2
0.5
0.8
1.3
0.9
1.8

0.8
0.3
0.8
0.8
1.0
0.9
0.9
0.9
0.5
1.3
2.1
0.6
0.5
0.8
2.9
1.0
1.5
0.7
2.8
2.7
1.0
1.4
1.9
0.7
7.3
3.3
1.1
1.1
0.9
0.9

0.5
0.6
0.7
0.9
1.1
1.0
0.9
0.9
0.5
0.9
2.3
0.7
0.7
0.7
2.7
0.7
2.2
0.8
4.0
1.1
0.7
1.2
4.0
0.7
8.7
6.5
1.4
1.3
0.8
1.0

0.2
0.2
0.2
0.2
5.7
0.3
5.1
4.2
2.6
5.5
3.6
0.2
1.0
3.4
1.2
3.5
5.5
0.3
12.1
5.6
0.4
0.3
0.4
0.2
7.3
2.5
5.0
0.2
3.8
0.3

Day 1
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AJ719858
AJ719718
AJ719295
AJ443395
AJ393939
AJ309540
AJ004940
AF432506
AF411083
AF070478
AF062392
AB031398
BU306841
BU144940
BU106686
BU336892
CR385186
CR387761
BU456843
BU468099
BX950657
CR390562
CR388632
BU212825
BU281664
BU377399
BU420694
BU433279
CR385201
CR385678
CR386845
CR389767
CR389813
CR390519
CR391100
DR431104

ITFG1
SC4MOL
INSIG1
TRIP13
ITPR3
IL6
HSPA8
FABP4
SFTPA1
MMP-13
MMP27
LEFTY2
NSDHL
ATF3
MKI67
HSPH1
PREDICTED: similar to CUG2
PREDICTED: similar to Gap
junction alpha-7 protein
PREDICTED: similar to Cancer
susceptibility candidate 5
PREDICTED: similar to Histone
protein Hist2h3c1
PREDICTED: chemokine (C-C
motif) receptor-like 1 isoform 1
PREDICTED: hypothetical
protein
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
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1.3
1.1
1.5
2.1
1.5
0.9
0.9
1.0
1.7
0.7
0.8
1.2
1.5
0.6
2.6
1.0
2.2

1.0
0.8
0.9
0.6
1.4
4.8
0.5
5.3
0.4
3.4
4.1
1.7
0.6
0.9
0.8
0.5
0.5

1.2
1.1
0.9
0.7
1.8
7.2
0.6
7.1
0.9
2.9
6.6
1.8
0.8
2.0
1.1
0.5
0.8

4.8
0.2
0.2
0.4
0.4
3.1
2.7
14.9
0.4
0.7
3.5
5.8
0.1
3.2
0.5
3.2
0.4

1.2

0.7

0.8

0.2

2.9

0.7

1.2

0.6

2.5

0.9

0.9

0.4

1.1

1.3

2.5

0.3

1.2

1.2

1.3

6.2

0.7
0.7
1.1
0.9
0.6
0.7
0.6
1.1
1.0
1.2
1.0
1.4
0.3
1.2

1.4
0.6
0.8
1.4
18.2
1.2
5.0
1.3
0.8
3.2
1.3
1.5
3.0
1.7

0.8
0.6
0.9
1.2
26.2
2.4
7.0
1.8
0.7
3.2
1.2
1.8
4.1
1.9

0.2
0.2
0.2
5.3
3.1
3.5
0.6
5.5
3.1
0.5
5.9
8.3
0.4
0.3

Table 2. Primers used for qRT-PCR.
Accession #
AJ711110
AF070478
AF062392
X03509
AJ309540
AF432506
X65459
AJ851480
AJ720861
AJ719295
AJ719718
U09350
U62026
M16199
X02009
AJ004940
AF411083
X16881
U12438
Y14971
NM_204305

Forward Primer
Reverse Primer
TGGTGGCTCGTTACCACAAG
TTCCCAAAGGGAGTCTCGAA
TCCCAAAACGCCAGAGAAAT
TCGCCAGAAAAACCTGTCCT
CAGCCCCAGTGAATTTCCTC
GACGGTTGGCCTTTTACCTG
CCAGGGGTATCTGGCACAAT
TCATGTTGCCACCTTTCTGC
CCTGTTCGCCTTTCAGACCT
GCCAGGTGCTTTGTGCTGTA
CCTGTTCGCCTTTCAGACCT
GCCAGGTGCTTTGTGCTGTA
GGACAGCCACAACTTTGACG
GCTGCTGATGATCACTGTGG
TGATGCAAGCACACGACTTG
ACCCACCAGGGTATTTGTCG
AGGTTCACCCAGATCCCAGA
CCACAGTCCCGTGTGCTAAA
CTGTTTCCCGACGAGCTCAT
GGTACAGCAGGCCAACAACA
GGCAGTGAACGACAGCGTTA
TAAATGGCTGCTGCAGAGGA
CGAAAGCAAATGGCTGTGAA
TGCTTCACCTCGAAGTTTGG
GAATGCTGGCACCAGGAAA
TCCGGAAAGGTTCCATCATC
CGCTGGTAAAGATGGGGAAT
CTTGGCGTCAGCTTCACATC
GATAGCGGCTGTGTGTTTCG
GAGGTCCCTGAGGTTGTTGC
CTGAATTCAAGCGCAAGCAC
TGACAGGGTACGCTTTGCAC
GTTGCTTTGCTAACGCCTTG
AGAGCTCCCAGACCAAGCAG
TTCCACGGGGACTCAGAGAT
TGCAAGGATTCCACATCAGG
GTCAGCAGGCTGGAGGTCTT
AGCAGAGGATGCTCCTCCTT
GGCTGTAGCTGCTGTCATGG
TATGCACTGGCATCGGAGTT
GGCACTGTCAAGGCTGAGAA
TGCATCTGCCCATTTGATGT
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Gene Symbol
VNN2
MMP-13
MMP27
CKB
IL6
FABP4
FABP7
ACSL1
LSS
INSIG1
SC4MOL
VIP
CENPF
IL8
LTF
HSPA8
SFTPA1
CDC2
RFC2
CXC chemokine K60
chGAPDH
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Table 3. Comparison of fold changes between microarray and qRT-PCR.
1 Day
3 Day
Gene
Gene Symbol
Micro
RTMicro
RTAccession #
array
PCR
array
PCR
AJ721110
VNN2
0.5
0.3
3.3
3.5
AF070478
MMP13
0.7
0.8
3.4
3.7
AF062392
MMP27
0.8
0.8
4.1
7.8
X03509
CKB
0.9
1.4
4.7
6.8
AJ309540
IL6
0.9
1.1
4.8
7.7
AF432506
FABP4
1.0
1.2
5.3
7.8
X65459
FABP7
1.1
1.5
0.3
0.8
AJ851480
ACSL1
1.2
0.9
7.3
6.0
AJ720861
LSS
1.3
1.1
1.1
0.7
AJ719295
Insulin induced gene 1
1.5
1.3
1.0
0.7
AJ719718
SC4MOL
1.1
1.7
0.8
0.9
U09350
VIP
2.0
2.4
0.2
0.1
U62026
CENPF
3.3
9.9
0.7
0.7
M16199
IL8
3.7
3.0
22.4
43.4
X02009
LTF
0.7
0.5
2.7
2.3
AJ004940
HSPA8
0.9
1.1
0.5
0.4
AF411083
SFTPA1
1.7
2.5
0.4
0.7
X16881
CDC2
1.9
2.2
0.4
0.3
U12438
RFC2
1.9
2.0
0.8
0.6
Y14971
CXC chemokine K60
3.7
7.9
17.3
60.3

5 Day
Micro
RTarray
PCR
6.5
8.7
2.9
3.8
6.6
23.7
5.5
11.0
7.2
37.1
7.1
33.4
0.8
1.1
8.7
8.0
1.3
1.1
0.9
0.9
1.1
1.3
0.3
0.2
1.4
2.2
26.8
172.7
3.6
5.2
0.6
0.5
0.9
0.9
0.7
0.6
1.0
0.9
19.7
206.4

7 Day
Micro
RTarray
PCR
2.5
2.6
0.7
0.5
3.5
7.9
2.0
3.3
3.1
5.7
15.0
10.0
0.2
0.3
7.3
7.6
0.2
0.1
0.2
0.1
0.2
0.2
0.2
0.2
0.6
0.6
18.5
39.0
3.2
4.1
2.7
3.2
0.4
0.3
0.4
0.4
0.3
0.2
11.3
38.2

Figure 1. ILTV infection in chicken embryonic lung cells. The chicken embryo lung cells were
infected with ILTV at a MOI of 0.1. The infected cells were visualized at 0, 1, 3, 5, and 7 dpi,
respectively, using a phase contrast microscope at 200X magnification.
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Figure 2. Groups of differentially expressed genes in the time course of ILTV infection. The
11,491 genes showing a signal to noise ratio (SNR) > 3 were sorted into three groups based on
alterations of fold changes at each dpi time point. The Y-axis represents log2 values of fold
changes and the X-axis indicates dpi time points.
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Figure 3. Patterns of differential expression. The mean value of each cluster was independently
plotted in the graph. The closed circle displays dpi time points The Y-axis indicates fold changes
by log2 value.
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Figure 4. Functional gene Ontology (GO) for differentially expressed genes. The 789 genes
were categorized into functional groups by the IPA program. Bars represent the number of genes
for each cluster. The Y-axis shows the total number of genes, and the X-axis indicates name of
clusters.
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Figure 5. Network 1 of gene network analysis. Molecular interactions among important focus
molecules are displayed at each dpi time points. Green represents down-regulation while red
depicts up-regulation. White symbols depict neighboring genes. The intensity of color represents
the average of log fold change in a given population. The numbers below the color change bar
denote log2 values. Symbols for each molecule are present according to molecular functions and
type of interactions.
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Figure 6. Genes of interest in the time course of ILTV infection. The expression levels for genes
of interest at each time point displayed by the bar graphs; Genes showing lower range of
alteration levels are displayed in (A), whereas genes ranging higher alteration levels displayed in
(B). The open, upward diagonal, vertical, downward diagonal and horizontal bars reflect 0, 1, 3,
5, and 7 dpi, respectively. Graphs show the mean ± SE.
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1. Abstract
Infectious laryngotracheitis virus (ILTV; gallid herpesvirus 1) infection causes high
mortality and huge economic losses in the poultry industry. To protect chickens against ILTV
infection, chicken-embryo origin (CEO) and tissue-culture origin (TCO) vaccines have been
used. However, the transmission of vaccine ILTV to unvaccinated chickens can cause severe
respiratory disease. Previously, host cell responses against wild-type ILTV infections were
determined by microarray analysis. In this study, a microarray analysis was performed to
understand host-vaccine ILTV interactions at the host gene transcription level. The 44 K chicken
oligo microarrays were used, and the results were compared to those found in wild-type ILTV
infection. Total RNAs extracted from vaccine ILTV infected chicken embryo lung cells at 1, 2, 3
and 4 days post infection (dpi), compared to 0 dpi, were subjected to microarray assay using the
two color hybridization method. Data analysis using JMP Genomics 5.0 and the Ingenuity
Pathway Analysis (IPA) program showed that 306 differentially expressed genes could be
grouped into a number of functional categories including cellular metabolism, immune response,
cancer, genetic disorder and cellular proliferation. Moreover, 10 possible gene networks were
created by the IPA program to show intermolecular connections. Interestingly, of 306
differentially expressed genes, 31 genes were commonly found in both wild-type ILTV and
vaccine ILTV infections. Eight of these commonly expressed genes, F2RL1, BMP2, IKBIP,
TYMS, C8orf79, F10, PTGS2 and NPY were expressed oppositely between the vaccine and the
wild-type ILTV infection. Intensive knowledge of gene expression and biological functionalities
by comparing host cell responses to either wild-type or vaccine ILTV infection can provide
insight into the pathogenesis and immune responses during ILTV infections.
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2. Introduction
Avian infectious laryngotracheitis virus (ILTV), named as Gallid herpesvirus 1, is a
member of the Iltovirus genus, Alpharherpesvirinae subfamily and Herpesviridae family. ILTV
has a linearized dsDNA genome of about 150kb in size which contains unique long (UL), unique
short (US) sequences flanked by inverted repeat (IR) and terminal repeat (TR) sequences [1, 2].
The genome encodes 80 predicted viral protein open reading frames (ORFs). ILTV infection
causes respiratory disease symptoms in chickens, pheasants, partridges and peafowl [3, 4] that
includes clinical signs of the extension of the neck, gasping, gurgling, rattling and coughing of
clotted blood [5]. ILTV usually causes the reduction of egg production and variable mortality
ranging from 5 to 70%, resulting in the severe economic losses in the poultry industry [6].
Two types of commercial live attenuated vaccines, chicken embryo origin (CEO) and tissue
culture origin (TCO) have been widely used to immunize chicken flocks against ILTV outbreak
[6, 7]. However, it was found that live vaccines infect the nervous system similar to that
exhibited in the wild-type ILTV infections, and could revert to become a causative agent to
induce vaccinal laryngotracheitis (VLT) by transmission to unvaccinated birds [8-10]. Moreover,
global ILTV outbreaks are mostly associated with CEO vaccines [11-13], and the genomic- and
antigenic characteristics between wild-type and vaccine ILTV are very similar [6].
Microarray analysis has become popular, along with the recent development of a RNA-seq
(RNA sequencing) technique using next-generation sequencing, to analyze massive gene
expression in different biological conditions. Microarrays have been performed intensively to
investigate host gene transcriptional responses to infections of various viruses such as hepatitis C
virus (HCV) [14], rice dwarf virus (RDV) [15], influenza virus [16], herpesvirus saimiri (HVS)
[17], human immunodeficiency virus (HIV) [18, 19], Japanese encephalitis virus (JEV) [20, 21],
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chicken anemia virus (CAV) [22], human cytomegalovirus (hCMV) [23], Epstein-Barr virus
(EBV) [24], infectious laryngotracheitis virus (ILTV) [25], varicella-zoster virus (VZV) [26],
alphaherpesvirus [27], Marek’s disease virus (MDV) [28] and herpes simplex virus type 1 (HSV1) [29], and in even vaccine strains including recombinant flavivirus [30], west nile/dengue 4
virus [31] and dengue virus [32].
Previously, we studied the differential gene expression of host responses against wildtype ILTV infection in cultured primary chicken embryo lung cells using microarray analysis
[25]. To compare and contrast host responses to the infection of either wild-type or vaccine
ILTV, primary chicken embryo lung cells were infected with live attenuated CEO vaccines and
host gene expression during a four days period post infection was determined using 44K chicken
oligo microarrays in the present study. Interestingly, genes showing opposite expression patterns
in vaccine ILTV infection were identified compared to wild-type ILTV infection. Results in this
study provide knowledge of differential regulation of host pathogenic and immunologic
responses against either wild-type or vaccine ILTV.
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3. Results and discussion
3.1. Profiling of differentially expressed host genes in vaccine ILTV infection
Primary chicken embryo lung cells at passage 1 were infected with 3 vaccination doses of
a live fowl laryngotracheitis vaccine, which is widely used in the poultry industry, and infected
cells were subjected to analysis for cytopathic effect (CPE) and virus infection validation at 1, 2,
3 and 4 days post infection (dpi). Although weak CPE, such as cell rounding, aggregation and
syncytia were observed at certain locations of plates at 1 and 2 dpi, infected cells began to
recover with healthy cells at 3 dpi, and no CPEs were observed at 4 dpi (Fig. 1A). To verify the
infection of vaccine ILTV, the expression of ILTV viral RNA was determined, and genes of
UL35 encoding small capsid protein and US5 encoding envelop glycoprotein J (gJ) were shown
to progressively increase their expression post infection though US5 expression began to be
detected from 2 dpi (Fig. 1B).
In the microarray assay using 44K genes, two approaches to avoid possibly hidden dye
effects were used: the use of RNA Spike-in controls synthesized from the Adenovirus E1A
transcriptomes containing different concentrations of dye in each set [33], and the dye-swap in
two replicates of four total replicates. No significant dye effects were detected in all microarray
slides (data not shown). The subsequent data analysis revealed that 1305 differentially expressed
genes at four dpi time points of vaccine ILTV infection were selected by one-way ANOVA test
using the JMP Genomics 5.0 program (Additional file 2). The 1035 differentially expressed
genes were subjected to the bioinformatics study using Ingenuity Pathways Analysis (IPA,
Ingenuity® Systems, www.ingenuity.com) to generate the gene networks and functional
annotations, resulted in 306 genes that recognized as mapped IDs (functionally known genes) by
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IPA program (Additional file 3). The list of 306 genes was analyzed for further bioinformatics
studies.

3.2. Quantitative reverse transcription-PCR (qPCR)
To validate the microarray results, expression of 18 genes of the 1,305 differentially
expressed genes were subjected to qPCR using the same RNA samples as those used in the
microarray and gene specific primer sets (Table 1 and Additional file 1). Of the 18 genes tested,
the expression pattern for 12 genes completely matched the microarray data at four time points.
The expression pattern for the remaining 6 genes also qualitatively matched to microarray data,
though they were not quantitatively matched (Table 1). With the comparison of the spike-in
controls, qPCR results indicated that the microarray data in this experiment were valid to
determine host gene expression responses against vaccine ILTV infection.

3.3. Top 10 differentially expressed genes.
Out of 306 mapped IDs, the top 10 most differentially expressed genes in ILTV vaccine
infection were selected by differences of standard deviation (SD) among all four dpi time points
(Table 2A). The general functions and possible roles in vaccine ILTV infection of the selected
genes are described briefly in Table 2B. These top 10 genes listed are involved in functions of
immune responses, inflammation, cell proliferation, apoptosis and cell-to-cell interactions.

3.4. Biological functions and gene networks of differentially expressed genes
Using the IPA program, 306 mapped genes were categorized into 75 biologically
functional groups, and the top 20 groups associated with greater numbers of genes, are shown in
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Fig. 2. The 20 functional groups are mostly related to cellular growth and proliferation, cellular
and tissue development, cell or tissue survival and interaction, diseases and disorders, and host
immune activation and inflammatory responses.
Network analysis by IPA to draw the connection of focus molecules displayed
relationships between the interacting genes. Of the 10 networks that were generated, the top 4
networks were identical among all four dpi time points, which may be due to the fact that the
algorithms of the IPA program generate a network by considering fold change values and pvalues of focus molecules in addition to their biological functions. The lists, top functions and
the main focused molecules of each network are shown in Additional file 4, and drawings of
interacting molecules in each network during the time course of all dpi time points are displayed
in Additional file 5.

3.5. Common genes found in both wild-type and vaccine ILTV infection
Previously, we reported 273 differentially expressed chicken genes mapped by the IPA
program for the wild-type ILTV infection, and the analysis of the functions and molecular
networks of these genes [25]. To find commonly involved host cellular mechanisms against both
wild-type and vaccine ILTV infection, the 306 differentially expressed genes in response to
vaccine ILTV infection were compared to the 273 differentially expressed genes found in the
previous wild-type ILTV infection study. Result showed that 31 genes were altered in their
expression in both wild-type and vaccine ILTV infections. Of these 31 genes, 23 genes showed a
similar differential expression pattern as found in the wild-type ILTV infection at 1 and 3 dpi,
and the GenBank accession, gene symbol and gene name are listed in Table 3. Interestingly,
eight of 31 genes were regulated in the opposite direction for expression patterns at 1 or 3 dpi
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between wild-type and vaccine ILTV (Fig.3 and Table 4). Those include coagulation factor II
(thrombin) receptor-like 1 (F2RL1, AJ851370), bone morphogenetic protein 2 (BMP2,
AY237249), inhibitor of kappa light polypeptide gene enhancer in B-cells kinase beta (IKBKB)
interacting protein (IKBIP, BX931418), thymidylate synthetase (TYMS, BX932834),
chromosome 8 open reading frame 79 (C8orf79, CR390951), coagulation factor X (F10,
D00844), prostaglandin-endoperoxide synthase 2 (PTGS2, M64990) and neuropeptide Y (NPY,
M87294).
Bone morphogenetic protein 2 (BMP2) was not altered in its expression in wild-type
ILTV infection at 3 dpi, while it was increased in vaccine ILTV infection at 3 dpi. The
expression of BMP2 was related to both the inhibition of tumor cell growth in carcino-embryonic
antigen (CEA) expressing cells and the induction of the differentiation of non-committed stem
cells to bone [34]. The functional role of BMP2 in herpesvirus (including ILTV) propagation has
not been studied, but the differential expression pattern of BMP2 in between wild-type and
vaccine ILTV suggests that the up-regulation of BMP2 in vaccine ILTV infection may support
the recovery of cellular structure at later phase of the infection.
Thymidylate synthase (TYMS) catalyzes the conversion of deoxyuridine 5’monophosphate (dUMP) to deoxythymidine 5’-monophosphate (dTMP), which is one of the four
essential components for DNA synthesis [35, 36]. Herpesviruses such as hCMV or murine CMV
(mCMV), that do not contain its own thymidine phosphorylase (TYMP), uses host TYMS to
replicate viral DNA [37, 38]. At 3 dpi, the expression of TYMS in wild-type ILTV infection was
decreased about 2 fold, while the expression of TYMS in vaccine ILTV infection was similar
between 1 and 3 dpi, which is 1.5 fold higher than that of uninfected control. The downregulation of TYMS in wild-type ILTV propagation may be due to the massive cell disruption
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generated by severe CPE as observed in the previous report [25]. However, the expression of
TYMS in vaccine ILTV infected cells was slightly elevated until 3dpi, which would support
continuous cell growth even during the time course of vaccine ILTV propagation. According to a
previous report, hCMV immediate early gene activates the expression of the TYMS gene to
efficiently replicate viral DNA genome [39]; similar expression patterns were observed at 1dpi
for both wild-type and vaccine ILTV replication. TYMS gene in wild-type ILTV infection might
be related to cell death due to the suppression of DNA replication of the host cell, and the severe
CPE production in wild-type ILTV infection might be caused by the down-regulation of TYMS
[25]. However, in vaccine ILTV infection, maintaining expression level of TYMS gene may be a
result of activation of the immune system by vaccine virus infection, resulting in cells that
recovered and proliferated with the marginally increased expression of TYMS gene.
Prostaglandin synthetase-2 (PTGS2), as known as (a. k. a.) cyclooxygenase-2 (COX2), is
responsible for prostanoid biosynthesis, and its functional roles are related to inflammation and
mitogenic stimuli [40]. Several reports have shown that viruses and viral products, such as HSV1 [41], HSV-2 [42] and Kaposi’s sarcoma-associated herpes virus (KSHV) [43, 44] induce
COX2 expression and prostaglandin production in various cell types and the induction of COX2
is associated with viral latency, inflammation and immune response. In the present study,
vaccine ILTV infection caused slight down-regulation of COX2 gene which may play a role in
mile inflammatory response found in vaccine ILTV infection compared to that wild-type ILTV
infection induced COX2 expression and led to massive CPE production. The transduction of
HSV-1 thymidine kinase has been known to enhance COX2 expression and enzymatic activity in
vitro and in vivo [45], suggesting that differential thymidine kinase activity between wild-type
and vaccine type ILTV may regulate the opposite pattern of COX2 gene expression during either
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wild-type or vaccine ILTV infection. Furthermore, the down-regulation of COX2 genes by
inhibitors blocked the cell-to-cell spread of hCMV [46]. These observations suggest that COX2
in avian host cells and thymidine kinase gene in ILTV can be potential targets to reduce the risk
of ILTV infection.
Neuropeptide Y (NPY) involves multiple cellular mechanisms related to both virus entry
into the central nervous system (CNS) and virus-induced neurological diseases. NPY protects
the nervous system from murine retrovirus-induced neurological disease [47]. The up-regulation
of NPY was observed in the reactivation of VZV from a latent infection in human sensory
trigeminal and dorsal ganglia, which are both sensory neurons [48]. It suggests that the upregulation of NPY in wild-type ILTV infection at 3 dpi may facilitate the latent infection in the
nervous system. In contrast, the continuous down-regulation of NPY in vaccine ILTV infection
might delay the latent infection by the up-regulation of immune responses to protect the host
from diseases.
Inhibitor of NF-kB (IkB) kinase subunit beta (IKBKB) interacting protein (IKBIP)
interacts with IKBKB triggering immune responses through the cytokine-activated intracellular
signaling pathway in various herpesviruses infections including HSV-1 [49], KSHV [50, 51],
EBV [52], hCMV [53], and gammaherpesvirus human herpesvirus 8 (HHV-8) [54]. The hCMV
infection induces the prevention of viral genome replication by the activation of NF-kB [55]. The
activation of IKK- β causes the degradation of IkB by ubiquitination of phosphorylated IkB
followed by the activation of NF-kB [56]. In addition, the free NF-kB enters the nucleus and
activates genes related to inflammation and immune responses. From this, it would appear that
the relative up-regulation of IKBIP in vaccine ILTV infection may cause the increased activity of
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NF- kB, and cause higher immune response levels, compared to those in the down-regulated
IKBIP gene in the wild-type ILTV infection .
F2RL1 and F10 are coagulation factors, and C8orf79 is an ORF region on chicken chromosome
8. The functional roles in virus infection of the genes have not been studied yet.

4. Conclusion
In this study, we examined host gene responses by vaccine ILTV infection. Unlike our
previous research of wild-type ILTV infection, vaccine ILTV infection showed weak CPEs and
cellular recovery, little massive cell death, and activated immune responses and non-pathogenic
inflammatory responses. Moreover, eight host genes were significantly modulated by vaccine
ILTV infection, and could be important regulators in non-pathogenic host immune responses.
Results in this study provide crucial insights into host immunologic and pathogenic responses
against vaccine ILTV infection.
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5. Materials and methods
5.1. Cell culture and vaccine ILTV infection
Primary chicken embryo lung cells were prepared as previously described [25]. All cell
culture reagents were purchased from Invitrogen Life Technologies (Carlsbad, CA, USA). Cells
were maintained at 37°C in a 5% CO2 incubator in 10 cm culture dishes by passaging every 3-4
days in 10ml growth medium consisting Dulbecco’s Modified Eagle Medium (DMEM, 0.45%
glucose) plus 10% fetal bovine serum (FBS), 100units/ml penicillin, 100µg/ml streptomycin, and
2mM L-glutamine. A modified live ILTV commercial vaccine, LT-Blen (Merial Limited, Duluth,
GA, USA), was used to infect the chicken embryonic lung cells by the amount equal to 3
vaccination doses. After incubation of infected cells for 1hr with gentle rocking every 15 min,
growth medium was added to each culture dish. The cells were incubated for up to 4 days. The
protocols used in this study were approved by both the Institutional Biosafety Committee (IBC;
permit number: 10007) of University of Arkansas and the Animal and Plant Health Inspection
Service (APHIS; permit number: 102743) of United States Department of Agriculture (USDA).

5.2. Total RNA extraction
TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) was used to extract
total RNA from uninfected- or vaccine ILTV infected chicken embryonic lung cells from 1 to 4
days post infection (dpi). Total RNA treated by DNase I (New England BioLabs Inc., Ipswich,
MA, USA) was re-purified by TRIzol reagent and quantified by Nanodrop1000
spectrophotometer (Thermo Scientific, Wilmington, DE, USA) and qualified quality assessed by
agarose gel (data not shown). To validate vaccine ILTV infection, expression of UL35 and US5
genes, in addition to chicken GAPDH (a host gene expression control), were determined by end-
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point reverse transcription PCR with gene specific primers. PCR amplicons were analyzed by
agarose gel electrophoresis and images were obtained using the GelDoc system (Biorad,
Hercules, CA, USA).

5.3. Probe labeling and microarray hybridization
Initially, 2 µg of total RNA was used to synthesize Cy3 or Cy5 labeled complementary
RNA (cRNA) using the Two Color Microarray Quick Labeling kit (Agilent Technologies, Palo
Alto, CA, USA) following the manufacturer’s instructions and as described previously [25]. To
avoid possible dye effects, RNA Spike-in controls, which were synthesized from the Adenovirus
E1A transcriptomes containing different concentrations of dye in each set [33], were added to
RNA samples as Spike-in A for Cy3 and Spike-in B for Cy5 and mixed with un-infected control
and vaccine ILTV infected samples at each dpi time point, respectively. For the additional
control of dye effects, the dyes were swapped in two replicates of four total replicates to confirm
further hidden dye effects. Each 825ng of Cy3 and Cy5 labeled cRNA probes were cohybridized on a 4X44K Agilent chicken oligo microarray (array ID: 015068). After washing and
drying, the slides were scanned using a Genepix 4000B scanner (Molecular Devices Corporation,
Sunnyvale, CA, USA) with the tolerance of saturation at 0.005%.

5.4. Microarray data analysis
Background-corrected red and green intensities for each spot were used in subsequent
analyses. Global normalization based on locally weighted linear regression (LOWESS) was
applied to the intensities by removing effects which arise from undesirable systematic variations
in microarray experiment. The ratio of signal intensities of corresponding spots to all Spike-ins
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used were compared to reference ratios reported previously [33]. All normalized data were
deposited in the Gene Expression Omnibus (GEO; accession number: GSE30269). Genes
showing both signal to noise ratio (SNR) of >3 (meaning foreground signals are three times
greater than background signals), and foreground intensity of > 100 at all time points were
considered as reliable signals. To identify differentially expressed genes throughout the four dpi
time points, normalized fold change values were subjected to statistical analysis by one-way
ANOVA test in JMP Genomics 5.0 (http://www.jmp.com/software/genomics/) licensed to the
Cell and Molecular Biology (CEMB) program of the University of Arkansas. Fold change values
representing differential expression were displayed as log2 conversion.

5.5. Quantitative reverse transcription-polymerase chain reaction (qPCR)
To verify the microarray data, qPCR was performed with 18 genes using gene specific
primer sets designed by Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3.cgi),
and the primer sets were synthesized by Integrated DNA Technologies (Coralville, IA, USA).
Primer information is shown in Additional file 1. Three μg of total RNA, which was used for the
microarray analysis, was converted to cDNA and qPCR was performed by following conditions:
40 cycles of denaturing 95°C for 30 s, annealing at 58 - 62°C for 1 min, extending at 72°C for 30
s, and finally extending at 72°C for 10 min. A non-template control (NTC) and an endogenous
loading control (chicken GAPDH) were used for the relative quantification. The fold change
values for the vaccine ILTV infected groups comparing to uninfected control were determined
by the -ΔΔCT method, which is comparable to log2 values in microarray [57].

5.6. Bioinformatics
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The Ingenuity Pathways Analysis (IPA) software version 9.0 (Ingenuity Systems®;
www.ingenity.com) was used to study biological functions and molecular interactions among
differentially expressed genes. IPA analyzes various bioinformatics tools including functional
annotation, clustering, and network discovery based on Ingenuity Knowledge Base, which is the
core technology of all IPA systems and the p-value developed from Right-tailed Fisher’s exact
test were mainly considered to interpret the interaction and functions of the differentially
expressed genes [58, 59]. For the network analysis, 10 networks and 35 molecules in each
network were limited to concentrate on the closest interacting focus molecules (focus genes= a
subset of uploaded significant genes having direct interactions with other genes in the database)
within the differentially expressed genes [60].
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Table 1. Validation of gene expression between microarray and qPCR.
Fold Change (Microarray / qPCR)
GenBank
Symbol
Day 1
Day 2
Day 3
Day 4
BX932962
SLC37A2
1.2 / 1.3
2.1 / 2.6
3.3 / 3.7
3.9 / 4.5
M60853
THBS2
1.5 / 1.8
2.0 / 2.5
2.8 / 2.8
3.3 / 3.3
BX933888
C1QTNF3
-0.2 / 0.1
1.2 / 2.0
1.9 / 2.5
2.7 / 3.4
BX933728
CAPSL
2.3 / 3.0
2.6 / 3.7
3.2 / 4.3
3.5 / 4.4
BX931297
CYTL1
1.0 / 1.7
1.4 / 2.8
2.7 / 4.2
2.9 / 4.4
CR352775
ALDOB
0.7 / 1.1
1.0 / 1.7
2.1 / 2.2
2.7 / 2.5
BX933478
MXRA5
0.8 / 1.5
1.7 / 3.0
2.5 / 3.7
3.0 / 4.4
BX935456
EGLN3
-2.7 / -2.0
-2.3 / -1.9
-1.7 / -1.4
-1.3 / -0.9
BX931599
VIPR2
1.7 / 2.0
2.3 / 2.9
2.9 / 3.6
3.1 / 5.1
CR385566
CLEC3B
0.2 / 1.0
0.4 / 2.2
1.3 / 2.4
1.4 / 3.1
M87294
NPY
-0.4 / -0.3
-0.9 / -0.6
-1.5 / -0. 9
-1.7 / -1.3
M80584
LUM
1.2 / 1.6
1. 5 / 2.3
1.9 / 2.5
2.5 / 3.2
M64990
PTGS2
-0.6 / -0.6
-0.8 / -0.3
-0.2 / -0.4
0.7 / 1.2
AB109635
HMGCR
0.4 / 0.4
0.2 / 0.6
-0.5 / -0.3
-0.9 / -0.6
BX936211
TMEM116
0.0 / 0.0
-0.3 / 0.3
-0.3 / -0.1
-1.3 / -0.7
X87609
FST
1.3 / 1.0
0.6 / 1.2
0.6 / 0.6
-0.3 / 0.2
D87992
ANPEP
-0.1 / -1.2
-0.5 / 0.5
-0.6 / 0.4
-1.4 / -0.2
AF505881
SCX
1.1 / 0.2
1.4 / -0.6
1.8 / 0.1
2.3 / -0.6
The gene expression levels of microarray were presented by log2 fold changes, whereas those of
qPCR were indicated by -∆∆Ct that are comparable to the log2 fold change values in microarray.
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Table 2. The 10 most differentially expressed genes in ILTV vaccine infection.
A. The gene list and fold changes at each day post infection (dpi)
GenBank
Symbol
1 dpi
2 dpi
3 dpi
4 dpi
BX933888 C1QTNF3
-0.2
1.2
2.0
2.7
AJ829443
AQP5
1.7
-0.4
-0.8
-0.6
AJ251273
CCK
0.2
-0.5
-1.1
-2.2
J00902
SPINK5
-0.4
-1.4
-2.1
-2.5
M60853
THBS2
1.5
2.0
2.8
3.3
AJ719394
PPIF
0.1
-0.1
-0.8
-1.7
CR390466
NMU
-0.1
-0.7
-1.3
-1.8
X80207
VLDLR
-0.4
-0.6
-1.0
-2.0
AJ851685 ADAM28
-1.1
-1.2
-1.8
-2.5
X87609
FST
1.3
0.6
0.6
-0.3

Mean
1.4
-0.1
-0.9
-1.6
2.4
-0.7
-1.0
-1.0
-1.7
0.6

Std
1.2
1.1
1.0
0.9
0.8
0.8
0.8
0.7
0.7
0.7

B. Gene functions
Symbol
Functions
 C1q and tumor necrosis factor related protein 3, a. k. a. CTRP3.
 Regulates angiogenesis by stimulating ERK1/2 and p38 MAPK [61].
 Cartonectin, an adipokine of the CTRP3 reduced IL6 and TNF production and
caused anti-inflammatory function by the suppression of NF-kB signaling [6264].
C1QTNF3  IL6 among cytomegalovirus secreted cytokines enhances angiogenesis and
survival of endothelial cells through impediment of apoptosis by blocking
(CTRP3)
caspase 3 and 7 [65].
 C1qTNF3 could accelerate embryonic growth and energy utilization for the
development of high feed efficiency (FE) broiler line [66].
 During ILTV vaccine infection, continuous increase of CTRP3 expression
until 4 dpi except 1 dpi, suggested to prevent inflammation responses, but
promote immune responses without massive cell death through cell recovery.
 Aquaporin 5, a water channel protein.
 Deficiency of Aquaporin 5 (AQP5) exacerbated lung injury by the infection of
pseudomonas aeruginosa [67].
 Down-regulation of AQP5 affects the increases of the proliferation and
migration of human corneal epithelial (CEP117) cell line through indirect
AQP5
activation of ERK pathway [68].
 Adenovirus infection to mouse lung caused the down-regulation of AQP5 gene
expression [69].
 The down-regulation of AQP5 gene expression in vaccine ILTV infection
might be associated to the reduced CPE and cell recovery in later dpi time
points.
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CCK

SPINK5

THBS2

PPIF

NMU

 Cholecystokinin, a peptide hormone of the gastrointestinal system to stimulate
the digestion of fat and protein.
 Adenovirus suppresses CCK mediated activation of c-Jun kinase (JNK).
inducing apoptosis or inflammatory responses on pancreatic acinar cells [70].
 Down-regulation of CCK expression in vaccine ILTV infected cells may result
in suppression of apoptotic cell death or inflammatory responses induced by
JNK pathway activation.
 Serine peptidase inhibitor, Kazal type 5 or chicken ovomucoid.
 Lymph-epithelial Kazal-type-related inhibitor (LEKTI).
 Inhibits immune and inflammatory responses in human primary keratinocytes
(HK) [71].
 Down-regulation of SPINK5 at all dpi time points may support the induction
of immune responses caused by vaccine ILTV infection.
 Thrombospondin 2, a potent inhibitor of tumor growth and angiogenesis and a
matricellular glycoprotein to mediate cell-to-cell interaction [72].
 Functions in angiogenesis in patients with early-stage non-small cell lung
cancer [73], and wound healing and development of exuberant granulation
tissue in horse [74].
 Up-regulation of THBS2 in vaccine ILTV infection may function in virus
spreads in infected cells.
 Peptidylprolyl isomerase F, one of the peptidyl-prolyl cis-trans isomerase
(PPIase) family proteins and a member of the mitochondrial permeability
transition (PT) pore in the inner mitochondrial membrane.
 Stimulates the cis-trans isomerization of proline imidic peptide bonds in
oligopeptides and accelerate the folding of proteins [75, 76].
 Apoptosis and necrosis of cells were induced by the activation of the PT pore
[77-79].
 Down-regulation of PPIF genes in vaccine ILTV infection may play a role in
cell death and recovery of cells.
 Neuromedin U, a multifunctional neuropeptide.
 Functions in conditions of pain and stress, the metabolism and homeostasis of
feeding and energy in body, immune and inflammatory diseases, smooth
muscle contraction, and the control of blood flow and pressure [80, 81].
 Deeply related to innate and adaptive immunity according to previous reports
regarding NMU and neuromedin U receptor 1 (NMU-R1).
 Expressed in antigen presenting cells (APCs) such as dendritic cells,
monocytes and B cells, and its receptor, NMU-R1, is fluently expressed in
immune cells such as natural killer cells, T cells, and monocytes [82].
 Induces early-phase inflammation through the degranulation in mast cells in
which NMU-R1 is highly expressed [83].
 Acts as an inflammatory mediator via the acceleration of IL-6 production in
macrophage [84].
 Down-regulation of NMU may inhibit inflammatory responses and elevate
immune responses.
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VLDVR

ADAM28

FST

 Very low density lipoprotein / vitellogenin receptor.
 Binds to baculovirus surface membrane to inhibit ligand-receptor interaction in
viral infection of HeLa cells [85].
 The meaning of down-regulation of VLDLR in ILTV vaccine infection in
addition to in other herpesvirus infection, is unknown.
 A disintegrin and metalloproteinase (ADAM) domain 28.
 Functions to cell-to-cell and cell-to-matrix interaction on the cell surface for
cancer cell proliferation, invasion and metastasis [86, 87].
 Up-regulated at carcinoma cells and functions the proliferation and progression
of human lung and breast cancer cells [88, 89].
 Acts as an inhibitor against human dental pulp stem cells (HDPSCs)
proliferation and an inducer of apoptosis of HDPSCs through the stimulation
of alkaline phosphatase (ALP) secretion and dentin sialophosphoprotein
(DSPP) [90].
 Degrades Insulin-like growth factor (IGF) binding protein 3 (IGFBP3) [91].
 The decreased expression of ADAM28 in vaccine ILTV infection, may
suppress the active induction of apoptosis.
 Follistatin.
 Inhibits follicle-stimulating hormone [92].
 Binds and neutralizes activin, a paracrine hormone of TGF-β superfamily,
which is related to the regulation of cell proliferation, apoptosis, and
carcinogenesis [93, 94].
 A member of fibrotic and wound healing response genes and cellular
proliferation genes and plays a role in muscle growth and strength in
nonhuman primates and liver proliferation. Moreover, the small plaque mutant
of VZV down-regulates FST [95].
 Up-regulation of FST at early phase (1 dpi) of vaccine ILTV infection may
play a role in the initiation of CPE.
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Table 3. The 23 genes showing a similar expression pattern in both wild-type and vaccine ILTV
infection.
GenBank

Symbol

Name

AB055783

CENPH

centromere protein H

AB105812

GEM

AF051399

FBLN1

AJ309540

IL6

AJ719326

MMP7

matrix metalloproteinase 7

AJ719339

NASP

nuclear autoantigenic sperm protein (histone-binding)

AJ720813

HNRNPD

AJ720861

LSS

AY265159

LHFPL5

BX930381

EMP1

epithelial membrane protein 1

BX931297

CYTL1

cytokine-like 1

BX932426

LRRC6

leucine rich repeat containing 6

BX932427

BATF3

basic leucine zipper transcription factor, ATF-like 3

BX933215

SOCS1

suppressor of cytokine signaling 1

BX933888

C1QTNF3

CR353484

C9orf91

CR387407

LOC424161

D16187

MAFK

V-maf musculoaponeurotic fibrosarcoma oncogene homolog K

M61145

PRNP

prion protein p27-30

M80584

LUM

lumican

U34977

FMOD

X91638

SMARCA2

Y09235

GLRX

GTP binding protein overexpressed in skeletal muscle
fibulin 1
interleukin 6

heterogeneous nuclear ribonucleoprotein D or AU-rich element
RNA binding protein 1, 37kDa
lanosterol synthase or 2,3-oxidosqualene-lanostrol cyclase
lipoma HMGIC fusion partner-like 5

C1q and tumor necrosis factor related protein 3
chromosome 9 open reading frame 91
similar to LOC129881 protein

fibromodulin
SWI/SNF related, matrix associated, actin dependent regulator of
chromatin, subfamily a, member 2
glutaredoxin or thioltransferase

The JMP Genomics 5.0 was used to compare the expression values at 1 and 3 dpi between wildtype and vaccine ILTV infection. The expression levels can be found in supplemental file 1 in
chapter 2 and supplemental file 3 in chapter 3.
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Table 4. The comparison of expression levels for eight genes showing opposite expression
pattern in between wild-type and vaccine ILTV infection.
ID

Wild-type ILTV
Day1

Wild-type ILTV
Day3

Vaccine ILTV
Day1

Vaccine ILTV
Day3

F2RL1

0.703

-0.051

0.924

0.614

BMP2

1.152

-0.047

1.425

1.011

IKBIP

-0.326

-0.262

0.445

0.185

TYMS

0.665

-0.989

0.678

0.622

C8orf79

0.544

-0.636

1.663

2.015

F10

-0.161

0.553

2.472

2.220

PTGS2

-0.236

1.370

-0.641

-0.223

NPY

-0.437

0.368

-0.400

-1.456

The values are presented by log2 ratio.
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Figure 1. Morphology of chicken embryo lung cells infected by vaccine ILTV and the
expression of ILTV genes. (A) Cell morphology and CPE development at 0, 1, 2, 3 and 4 dpi.
Phase contrast microscopic images are displayed at 200× magnification. (B) ILTV gene
expression (UL35 and US5) at 0, 1, 2, 3 and 4 dpi by RT-PCR. Expression of chicken GAPDH
(chGAPDH) was used as an endogenous control.
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Figure 2. Functional groups of differentially expressed genes. Out of 75 functional groups, the
top 20 groups considered by gene numbers related to each category were displayed.
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Figure 3. Eight differently expressed genes in both infections. Relative expressions were compared for eight genes in between wildtype and vaccine ILTV infection. The upward diagonal, open, downward diagonal and close bar represent ILTV infected samples for
wild-type at 1 dpi, wild-type at 3 dpi, vaccine at 1 dpi, and vaccine at 3 dpi, respectively.

119

CHAPTER 4

Kinetic analysis of infectious laryngotracheitis virus (ILTV) gene expression during the
lytic replication phase in cultured cells

Jeong Yoon Lee1,2, Byung-Whi Kong1,2*

1

Cell and Molecular Biology Graduate Program, 2Department of Poultry Science,
University of Arkansas, Fayetteville, AR 72701, USA

120

1. Abstract
Avian infectious laryngotracheitis virus (ILTV; gallid herpesvirus 1) is a member of the
Iltovirus genus of the Alphaherpesvirinae subfamily of the Herpesviridae family. ILTV encodes
80 predicted open reading frames (ORFs) in about 150kb linearized dsDNA that contains UL
region and US region flanked by IR and TR regions. The regulatory mechanisms of ILTV gene
expression in infected cells are still unclear. In this study, the expression levels of all 76 genes
known to be expressed in the ILTV genome were determined by quantitative PCR (qPCR) using
SYBR green staining method with total RNA extracted from ILTV infected cells at 1, 3, 5 and 7
dpi. It was observed that ICP4, UL21 and UL42 showed unique expression patterns at all dpi
time points, whereby ICP4 showed the highest expression levels at all time points. UL21 showed
similarly high expression levels between 5 and 7 dpi after an initial steadily increase, and UL42
showed the fluctuations of expression level at all time points. UL17, UL28, UL29, UL50 and
UL52 showed decreased expression at 3 dpi compared to 1 dpi, and increased again until 7 dpi.
Twenty nine ILTV genes including UL-1, UL0, UL1, UL2, UL3, UL3.5, UL6, UL9, UL11,
UL12, UL15, UL24, UL25, UL26, UL26.5, UL27, UL38, UL44, UL45, UL49, UL49.5, ORFA,
ORFB, US2, US4, US5, US6, US7 and sORF1 indicated progressively increased with days post
infection (dpi) time points. The relative expression levels of the remaining, 39 ILTV genes
including UL4, UL5, UL7, UL8, UL10, UL13, UL14, UL18, UL19, UL20, UL22, UL23, UL30,
UL31, UL32, UL33, UL34, UL35, UL36, UL37, UL39, UL40, UL41, UL43, UL46, UL48,
UL51, UL53, UL54, UL56, ORFC, ORFD, ORFE, ORFF, US3, US8, US8A, US10, sORF4/3,
are not different at 1 and 3 dpi, and then increased expression by 7 dpi. These results may
provide insights into the molecular mechanisms of ILTV pathogenesis during the cytolytic
infection phase.
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2. Introduction
ILT as chicken respiratory disease is an economically important disease for the poultry
industry worldwide. ILT causes a severe illness resulting in weight loss, reduction of egg
production and high mortality rates, up to 70%. Currently, chicken embryo-origin (CEO) and
tissue culture-origin (TCO) vaccines, which are live attenuated vaccines, have been broadly used
to prevent ILT outbreaks in flocks, but the reversion of vaccine ILTV into virulent virus during
passage in chickens became a current threat of ILT outbreak called vaccinal laryngotracheitis
(VLT) [1-3]. ILTV is a causative agent for ILTV and ILTV Infected chickens or vaccinated
chickens can transmit latently infected ILTV to uninfected chickens via respiratory route by
coughing and sneezing or by bird-to-bird contact.
ILT virus (ILTV), which is a member of the Iltovirus genus of the Alphaherpesvirinae, is
a causative agent of ILT. The dsDNA ILTV genome, which is about 150kb in size, includes one
unique long region (UL), one unique short region (US), one inverted repeat (IR) and one
terminal repeat (TR) flanking the US region [4, 5]. The ILTV genome encodes 80 predicted open
reading frames (ORFs) expressing functional or structural proteins [6]. Previously, a mosaic
ILTV genome sequence combined with partial sequences from 6 different ILTV strains has been
used for ILTV research since 2006 [7]. Recently, the complete genome sequence of a single
Australian commercial live attenuated ILTV vaccine strain (Serva) is reported in 2011[5]. Taken
together, discriminatively, 5 ORFs named ORF A, B, C, D and E are located in near ORIL in the
UL region in the ILTV genome [8]. Also, like typical herpesvirus, three DNA replication origins,
one OriL in the UL region and two identical ORIS in the IR and TR regions, are included in the
ILTV genome. Furthermore, 63 genes in the ILTV genome show homologies with the HSV-1
genome [9], and it could be inferred that those proteins in both ILTV and HSV-1 genomes have

122

similar structure and function. Of 63 genes, 11 genes encode glycoproteins namely gB, gC, gD,
gE, gG, gH, gI, gJ, gK, gL and gM, which function immunogenic and antigenic activity in ILTV
infected cells.
Normally, herpesvirus gene expression can be classified into three stages; immediateearly (IE), early (E) and late (L). Usually, proteins expressed in the IE stage function as viral
gene transcription regulators, E stage proteins play roles in viral genome replication, and finally
L proteins are produced for structure proteins of virus particles [10]. However, kinetic expression
patterns of ILTV during lytic infection have not been determined. This study uses a time course
approach to gain insight into ILTV gene expression in cultured chicken embryo lung cells using
qPCR and to help fully understand ILTV pathogenesis and the control mechanism of ILTV genes.
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3. Materials and methods
3.1. Primary cell culture and ILTV infection
Primary chicken embryo lung cells were prepared from 19 days old SPF chicken embryos
as previously described [11]. ILTV purchased from the National Veterinary Services Laboratory
(NVSL) was used to infect chicken embryo lung cells. The infected cells were incubated at a
37°C and 5% CO2 incubator with gently rocking every 15 min for 1h. Ten ml of Dulbecco’s
Modified Eagle Medium (DMEM, Invitrogen, Garlsbad, CA, USA) containing 10% fetal bovine
serum (FBS), 100 units/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine
(Invitrogen Life Technologies, Carlsbad, CA, USA) were added in infected cells. Cells were
incubated at 37°C and 5% CO2 for up to 7 days. The protocol used for this study was approved
by both the Institutional Biosafety Committee (IBC; permit number: 10007) of University of
Arkansas and the Animal and Plant Health Inspection Service (APHIS; permit number: 102743)
of United States Department of Agriculture (USDA).

3.2. Total RNA extraction
The total RNA was extracted from uninfected or ILTV infected primary chicken embryo
lung cells at 1, 3, 5 and 7 days post infection (dpi) using TRIzol reagent (Invitrogen Life
Technologies, Carlsbad, CA, USA) following manufacturer’s instructions. After treating DNaseI
(New England BioLabs Inc., Ipswich, MA, USA), the total RNA was re-extracted by the TRIzol
reagent. The quantification of the total RNA was determined by NanoDrop1000
spectrophotometer (Thermo Scientific, Wilmington, DE, USA) and the quality was determined
by the fractionation of 18S and 28S RNAs on an agarose gel (data not shown).
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3.3. qPCR
qPCR was performed for all known 76 genes encoded in the ILTV genome using gene
specific primer sets. Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3.cgi) was
used to design primers synthesized by Integrated DNA Technologies (Coralville, IA, USA).
Primer information is provided in Table 1. Briefly, 3 µg of the total RNA were initially used for
reverse transcription and the qPCR was performed under the following conditions: total 40
cycles, denaturation at 95°C for 30 s, annealing at 58°C for 1 min, extension at 72°C for 30 s,
and one cycle of final extension at 72°C for 10 min. A non-template control (NTC) and
endogenous loading control (reference; chicken GAPDH) were used for the relative
quantification. The relative expression levels of ILTV infection were calculated with Cp value
which is Ctref-Ctsample adding 24 as a specific constant in order to revise negative values to all
positive value [12].

3.4. Data analysis
All gene expression values were subject to one-way ANOVA test using JMP Genomics
5.0 (http://www.jmp.com/software/genomics/) licensed for Cell and Molecular Biology (CEMB)
of the University of Arkansas. The significant differences of the ILTV gene expression levels at
each time point were considered by p < 0.05.
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4. Results and disscussion
4.1. Highest, fluctuation and invariable expression patterns in ILTV genes
Of the viral genes determined, UL21, UL42 and ICP4 showed a distinct gene expression
pattern during ILTV propagation (Figure 1).
Of these three genes, ICP4 consistently expressed the highest level compared to other
genes during all dpi time points with Cp values ranging from 17.15 to 17.67. ICP4 of herpes
simplex virus was also highly expressed in the murine trigeminal ganglia until 7 dpi during lytic
infection [13]. ICP4 as an immediate early gene is known to regulates many early and late genes
[14-16]. ICP4 localizes in intranuclear distribution or in globular compartments at early or late
stage of infection, respectively [17].
The expression of UL21, a tegument protein functioning in virion morphogenesis,
increased from 1 dpi to 5 dpi and remained elevated on 7 dpi. Specifically, Cp expression levels
were 1.33, 3.75, 7.09, and 8.06 at 1, 3, 5 and 7 dpi, respectively. The UL21gene, which is
conserved among mammalian herpesviruses [18], is known to function in herpesvirus virulence
and virus propagation in cultured cells during infections of HSV-1 [19] and PrV [20-23]. In
addition, the UL21 protein in HSV-1 infection is associated with virus transportation through
microtubules [23]. Also, UL21 in PrV infection is required for package of UL46, UL49 and US3
into mature virions [24] and is also related to retrograde and neuronal invasiveness in vitro and in
vivo [25]. Thus, ILTV UL21 may play critical roles in virus propagation and ILTV virulence by
progressively increasing its protein amount during lytic infection phase.
Expression levels of UL42, which codes for a DNA polymerase processivity subunit that
functions in DNA replication [26], fluctuated between time points determined. The Cp values
were 8.23, 12.43, 7.92, and 14.93 on 1, 3, 5 and 7 dpi, respectively. UL42 has been shown for
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other herpesviruses to play a role in viral DNA replication [27, 28]. Additionally, in HSV-1
infections, it appears to be also important in DNA replication for lytic viral growth [29]. The
UL42 gene is expressed early under the regulation of immediate-early IE63 (ICP4) and can be
detected at as early as 3 hpi in HSV-1 infection [30-32]. Likewise, ILTV UL42 examined here
was expressed already on early lytic infection stages, 1 dpi, presumably to drive DNA replication.
The reason for the biphasic nature of UL42 expression exhibiting a decrease at 5 dpi is unknown.

4.2. Genes showing decreased expression at 3 dpi
The similar levels of expressions of UL17, UL28, UL29, UL50 and UL52 observed at 1
dpi remained at the same levels on 3 dpi and increased further by 7 dpi (Figure 2). The Cp
expression levels of UL17, DNA packing tegument protein related to DNA encapsidation and
capsid transport, were 6.84, 5.89, 10.60 and 12.80 at 1, 3, 5 and 7 dpi, respectively. The UL17 in
HSV-1 and PrV shown to be involved in viral capsid cleavage and packaging by association of
immature B-type capsids [18, 33]. In Marek’s disease virus type 1 (MDV-1) infection, UL17 was
formed to have a fundamental role for virus growth in the nucleus [34]. Likewise, ILTV UL17
expression is increased at the later stages of lytic infection presumably because of its function in
virion packaging. UL28, which codes for a DNA packaging terminase subunit during DNA
encapsidation, showed Cp expression as of 4.45, 2.49, 6.56 and 8.59 at 1, 3, 5 and 7 dpi,
respectively. In HSV-1 infection, UL28 play an important role in the maturation of capsid
protein [35], DNA cleavage and encapsidation of viral gene through interacting with UL33 [36,
37]. Previously, the homologues of UL28 were reported as a conserved region between
herpesviruses such as MDV-2, bovine herpesvirus 1 (BHV-1) and green turtle herpesvirus
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(GTHV) [38-40]. Similar to UL17 shown above, the functional role of ILTV UL28 in virion
maturation is correlated to its increased expression at the late phase of lytic infection.
The UL29, single-stranded DNA-binding protein in DNA replication [29] showed Cp
expression of 5.82, 4.56, 9.91 and 12.42 at 1, 3, 5 and 7 dpi, respectively. The Cp expressions of
the UL50, deoxyuridine triphosphatase nucleotide metabolism, were 8.17, 7.61, 11.72 and 13.75
at 1, 3, 5 and 7 dpi, respectivley. UL50 is closely conserved in herpesviruses such as BHV-1,
equine herpesvirus type 1 (EHV-1), HSV-1 and varicella zoster virus (VZV) [41-45]. UL50
deletion mutant of ILTV resulted in decreased cell-to-cell spread in vitro and attenuation in vivo
and in efficient replication in the respiratory tract of infected hosts [46], demonstrating the
importance of the virus gene in viral replication and virulence. The expression levels of UL52,
helicase-primase subunit DNA replication, were 4.84, 3.02, 6.88 and 10.58 at 1, 3, 5 and 7 dpi,
respectively. In HSV-1, UL52 is a subunit of a three polypeptide complex consisting of UL5,
UL8 and UL52 proteins, the functions as a DNA helicase-primase [47]. Particularly, UL52 has
the primase activity within the helicase-primase complex and the function is conserved among
different herpesviruses such as VZV, Epstein-Barr virus (EBV), human cytomegalovirus (hCMV)
and EHV-1 [48]. Generally, the viral gene transcription machinery is activated earlier than viral
genomic DNA replication pathways. Therefore, the large increase of expression of UL29, UL50
and UL52, which are responsible mainly in DNA replication, may be correlated to the later onset
of ILTV genome replication.

4.3. The typical expression patterns among ILTV genes.
Most of the ILTV genes were expressed in similar patterns showing continuous increase
from 1 through 7 dpi or 3 through 7 dpi (Table 2 and 3). In total, 29 genes out of 76 ILTV genes
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showed the progressive increase of gene expression until 7 dpi (Table 2). The mean values of Cp
expression for each dpi time point were 7.51 ± 0.25, 8.88 ± 0.18, 12.52 ± 0.10 and 15.15± 0.15 at
1, 3, 5 and 7 dpi, respectively. Among the 29 genes, 23 and 6 genes were in the UL (UL-1, 0, 1,
2, 3, 3.5, 6, 9, 11,12,15, 24, 25, 26, 26.5, 27, 38, 44, 45, 49, ORF-A and OEF-B) and US (US2, 4,
5, 6, 7 and sORF1) region, respectively. In contrast, 39 genes showed no significant changes of
gene expression between 1 dpi (6.46 ± 0.34 Cp) and 3 dpi (6.52 ± 0.33 Cp), but their expression
increased further at 5 dpi (10.51 ± 0.17 Cp) and 7 dpi (13.20 ± 0.11 Cp) (Table 3). Among 39
genes, 34 genes (UL4, 5, 7, 8, 10, 13, 14, 18, 19, 20, 22, 23, 30, 31, 32, 33, 34, 35, 36, 37, 39, 40,
41, 43, 46, 48, 51, 53, 54, 56, ORF-C, ORF-D, ORF-E and ORF-F) and 5 genes (US3, 8, 8A, 10
and sORF4/3) were in the UL and US region, respectively.
Kinetic analysis of ILTV gene expression showed critical patterns compared to other
herpesviruses. In the case of human herpesvirus (HHV)-6B, most HHV-6B genes were actively
expressed until 8 hours post infection (hpi). Late genes slowly increased until 48 hpi [49], and
after this time only late genes and few early and delayed-early genes were expressed until 60 hpi
[50]. Most of the genes encoding HHV-8, which is also known as KSHV, were highly expressed
within 48 hpi, and the expression level of most genes decreased after 48 hours [51]. In infected
NIH 3T3 fibroblast cells with mCMV, late genes were detected at 48 hpi [52]. The expressions
of murine herpesvirus (MHV)-68 genes in infected baby hamster kidney (BHK)-21 cells peaked
until 32 hpi and then gradually decreased or remained at similar level until 5 dpi [53]. Among the
genes, the expression of IE and E genes were reached to a peak by 8 to 12 hpi. However, most of
ILTV genes were continuously up-regulated until 7 dpi.
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5. Conclusion
In this study, expression of ILTV genes was determined at 1, 3, 5 and 7 dpi by qPCR
using SYBR. Though most of ILTV genes continuously increased during lytic infection period,
some genes such as ICP4, UL21 and UL42 showed unique expression patterns. Also, the
observation of elevated ILTV gene expression until 7 dpi was not previously reported for other
herpesviruses. Therefore, the findings of ILTV gene expression may provide information on
ILTV life cycle and pathogenesis.
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Table 1. The primer sets for qPCR in ILTV infected chicken embryo lung cells.
Gene
Name
UL-1
UL0
UL1
UL2
UL3
UL3.5
UL4
UL5
UL6
UL7
UL8
UL9
UL10
UL11
UL12
UL13
UL14
UL15
UL17
UL18
UL19
UL20
UL21
UL22
UL23
UL24
UL25
UL26
UL26.5
UL27
UL28
UL29
UL30
UL31
UL32
UL33
UL34

Forward Primer (5' → 3')

Reverse Primer (5' → 3')

TGT GCG ATG CTC CAA ATA GC
CTT GAC GTC CGT GCT GTC AT
TCC GTG TTT ACG CAC AGA GG
CAC CCC CTA GGG ACA CTG AA
TTC GTT TTG ACA TGC CCT TG
GTG AGG AAA ATC GGG TCT CG
TGG AGG AAT GCG GTT TAT TTG
AAC AAC GTT CGT TGG CAG AA
ATT TCG AAC CCT CTG GCA AA
ATC ATC TAG GCG CAC ACA CG
CCT GGG CTT CGA GAA GAG AA
TTT CAA ACG TCG TTG CGT TC
GCC CTT AGC AGT CCA GGT TG
TCT GTG GAC ACC TCG GAG AAT
GGC AGA GAA GCG TTC GAG TT
GCG CAT CGA TCT ACG AGA AA
AGG TGA CCC TGA TCG CAG AG
TAG TGC GGC ATC GGT ATC TG
GGC AAA AAC CGG CAA TAT GT
CAG AAG CTT GCG TGG GAC TA
CAC TTT TTC CGC CCA TGA TT
CCA ATT CAA TCC GCC TCT CT
AGT TTC GGG GCT CTG GAT TT
GAC AGC AGT TCC GTG TGG TC
GAC GGC AAC CTC TCC AAT TT
CTC GGA GCA AAA CTG CAC AC
GAT CTG GAA AGG CGG AAC AG
GAC CTG CCG AGA GGA CTG TT
ACG GAG CAG CAG CTA TGT GA
TAG CCT GGC GCT TAC AGG TT
TTT CCC GTA CCC AAG CGT AG
ACG CGC TCC ATT TGA GTT TT
CCA AAT TCG AGA CCC AGG AC
CGT ACC AGC GAA TAC GTC CA
TCG AAG AGC ATG CCA GTG TT
TTA GCG GAA AGG CCA CTC TC
GAA CGA CAG CGA GTC TGG TG

ACA ATT CCT GCG ACA CTC CA
CCA CTC ACG GTG GAT TTG AA
AGA TAA CGG TGC GCG AAT TT
ACT GCA ATC CGC AAG ATG TG
TTG ACT GTG TTT CCG GAT CG
CGG CTG CGT TAC AGG GTA AT
ATC ATT GTT GCG ACG GGA TT
ACC GGA GAT GCC GTG TCT AT
TGG CAG TGA TCT CGG AAA TG
ATC CAG ATG GAT GGG GAA AA
TAG CGG TGC TTA CGG TGT TG
CGC CCC CAG TTA GTC GTA TC
TTA GTC CGC AAG CAG GGT TT
TAG GGA CAA GCG CTC TCC AG
CGC AGG ACT TTG AAC AGC AG
TCC GCA TCC CAG TGA CAT AG
GCA GTA GCG TCG GAG GAT TT
CTA TTT CGC GTG CGT TTT CA
TAG CCT GTT TGG CTG ACG TG
TTC CAT GGG CGA AAA ATG AT
GCT CTC TCT CCG AAG GTG GA
TCA CCA TCA CGT TCT TTT TCG
GCT CGG GCA CTA TCC TTG TC
ACT GTT AGC CGG TGC CAA CT
CGC CGC GTT GTA CTT CTT TA
AGC GAT TAT GGC AAC GGA TT
AGT TTG CAA TGC CGA TGA GA
GGC ATT CGC AAA AAG AGC AT
CCG GCA ACC TCT TTT TGA AG
TCA GAA CCG CCA ACT GAT TG
AGA GCG TGC TCC GAA ATA GC
TCT GTC TCC TGC GCT CCA TA
TCT GGC CAC GAG ACA TTG TT
AAA CAG AGC ACG CCA CTT CA
GGC GTC TAT TTT GCC TCA CC
CCG GAG GCG ATA GGT CAT AA
TGG GGG ACC GTC AAG TTT AG
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UL35
UL36
UL37
UL38
UL39
UL40
UL41
UL42
UL43
UL44
UL45
UL46
UL48
UL49
UL49.5
UL50
UL51
UL52
UL53
UL54
UL56
US2
US3
US4
US5
US6
US7
US8
US8A
US10
sORF1
sORF4/3
ICP4
ORFA
ORFB
ORFC
ORFD
ORFE
ORFF

AAA CCG AGC TCC AAT GCT TC
GCG GCT TTG GCT ACT TTG AT
CGC TTT CAG ACA CCC CTA CC
ACG AGC CCA GGG AAA TTC TT
AGA GCG GGA ACC ACA GGT TA
TTT TTC GTG GCG TCC TTT G
AGG ATC CTG AGG GCG GTA AT
GGA GGA GCG CCT CAT ACA AC
CTG GCA TTC CAT TTG GTG TC
AGC TCG GTG ACC CCA TTC TA
GGG CAC GGC AAG AAA GTT TA
TCT CGA TGT CCC ATT TGG TG
TGA GGA TGA TGC GAC TGA CC
ATT CGA ACA CCC CTG GTC TG
GCC GTG GGA AAG GAG TTT TA
TAG CTG TGC CAC TCG GTC AC
GCA GAC AGG ACG ATG ATG CT
CCA GCA TGT CAG CCA AGT GT
GCA CGG GTC AGC AAG TAA CA
ACG TTT CGC AAC TCC TTC GT
TGG GTT GGA GTG GCC TTA AT
CGC TCC ACT CGG GAC TTA CT
CAG CTC ATG TCA GCG GTC TC
CCG GGA TAC CTG ATT TCG AC
TCC AGC TAA TGT GCC TGT CG
GGA ATG TGG CGA CGT ACA AC
TGC GTG CGA AAT AAA CAA GG
AGA CGA GAA GGC TCC AGC AC
GGC ACC GGT AAG AAA ACT GC
GCA ACG GGT TGG GAG AAT TA
ACT GCC GAG GTC CTT TCT CA
GAA CCT TCG GGG AGG TCT TC
ACA GGG GAT GGA CCA TGA AC
TCT CCT GGG ATC TGC GTT CT
TTG CAG GTT GGA GTG CCT AA
AAT CTG GCG TTG GTC CAC TT
AAT GTG AAC GCA CTG CCA AG
CTA TCT CAT CGG GGG TCC AA
GAG AAT AGC TGC CCC TGC TG
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GCG TTG TCT CAC TCC AAA CG
AAA ACG AGC TCG AGG GAG TG
ATC CGC GGA CGC TAC AGT AT
GCG ATG GCC CTT GTA TCT TC
GCC CTC AAC GCT AGT CAT CC
TTC ATC GCG ACT GAT GAG GT
CCT TTG CCT GGA CGC TAT GT
GGT GGT GGG ATG GGC TAA TA
GTG TAT GGG TGG CCG TTT TT
ACT AAG CTG GCT GGG TGT CG
CGC CTG ACT GGA TTC AAC AT
TGT CCG GGA AAA CCC AGT AG
GTA CTT TGG CGC ATT GAC CA
GAT GGC CGT AAT CCC CTT CT
CAT TCC GTG TCC TGG TGT CA
GAC CCG ATA CAT GTG CAG GA
CCA TGC CGA GTA GTT CCA AA
TTT TTG TCG TTC CGC ATT TG
CGT CAT GGA AGT GGC AGA CT
TTG GGA AAG AAA TCG GGA TG
GGA TGC GGA TAC AAC CTT CC
AGT TTC CGG GGA GCT GTT TT
TGT CTT GCC GTC GCA GTT TA
AGG GAT CCA TTG CCA GAC AC
CTG GCG CGA TAT CTT TTT CC
TTC GCG ATA CAA GGG TGC TA
TTA TTG AGT CGG GCG AGC TT
CAT GAA ACG GCA GCA TTT GT
CGC GTG GTT GTC AGA TTC C
TAC GGC TCT CGT CCT CGA A
GGG GTC GGT TTG GAC TCA TA
GGC GAT AAG GAT AGG CAT GG
GCC AAT CCG AAA TCA GCT TC
TCC TTC GCC TAT CTC GAA GC
AGC ACA CTG CAG GAT CCA AA
CGC AAA CTT GAG ATG GGA CA
ATC TTT CCA GCT CCG ACG AA
ATG TGC GGC AAG TTT CTG TG
CCT GGG TCC TCT TCA CGT TC

Table 2. The list of virus genes continuously increased at all time points in ILTV infected
chicken embryo lung cells.
1 dpi
3 dpi
5 dpi
7 dpi
†
Cp
Cp
Cp
Cp
Protein§
Genes
‡
SE
SE
SE
SE
Functions§
9.41a
10.64b
13.48c
15.28d
Protein LORF2
UL-1
0.16
0.12
0.11
0.09
Unknown
UL0

UL1

UL2

UL3

UL3.5

UL6

UL9

UL11

UL12

UL15

UL24

5.63a

7.21b

11.49c

14.60d

Protein UL0

0.12

0.22

0.07

0.04

Unknown

7.35a

9.71b

13.60c

16.33d

Envelope glycoprotein L

0.14

0.14

0.08

0.12

Cell entry: cell-to-cell spread

7.06a

8.73b

12.62c

15.74d

Uracil-DNA glycosylase

0.11

0.13

0.13

0.26

DNA repair

6.99a

7.94b

11.28c

13.33d

Nuclear protein UL3

0.25

0.19

0.06

0.14

Unknown

8.13a

9.29b

13.03c

17.00d

Protein V57

0.17

0.14

0.08

0.01

Possibly virion morphogenesis

4.19a

6.14b

8.85c

12.01d

Capsid portal protein

0.48

0.40

0.21

0.23

DNA encapsidation

1.65a

3.08b

5.51c

7.14d

0.39

0.46

0.34

0.03

DNA replication origin-binding
helicase
DNA replication

8.93a

9.98b

13.99c

16.76d

Myristylated tegument protein

0.06

0.24

0.04

0.13

Virion morphogenesis

9.34a

10.72b

14.27c

17.19d

Deoxyribonuclease

0.10

0.05

0.09

0.10

DNA processing

5.87a

6.70b

9.63c

11.88d

DNA packing terminase subunit 1

0.35

0.18

0.11

0.17

DNA encapsidation

4.76a

5.55b

9.55c

13.22d

Nuclear protein UL24

0.31

0.26

0.03

0.12

Unknown
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UL25

UL26

UL26.5

UL27

UL38

UL44

UL45

UL49

UL49.5

ORF-A

ORF-B

US2

US4

5.79a

7.02b

10.46c

14.02d

0.50

0.12

0.12

0.07

DNA packaging tegument protein
UL25
DNA encapsidation

5.37a

6.43b

10.33c

13.34d

Capsid maturation protease

0.10

0.06

0.16

0.15

Capsid mophogenesis

9.43a

10.26b

14.22c

17.16d

Capsid scaffold protein

0.20

0.14

0.08

0.23

Capsid morphogenesis

6.74a

7.54b

11.68c

14.46d

Envelope glycoprotein B

0.11

0.14

0.12

0.18

Cell entry: cell-to-cell spread

4.64a

6.10b

10.21c

13.85d

Capsid triplex subunit 1

0.53

0.23

0.03

0.03

Capsid morphogenesis

8.78a

9.84b

13.50c

15.91d

Envelope glycoprotein C

0.08

0.14

0.02

0.06

Cell attachment

6.67a

9.29b

12.94c

15.28d

Membrane protein UL45

0.36

0.09

0.11

0.16

Possibly membrane fusion

10.15a

11.44b

15.05c

18.00d

Tegument protein VP22

0.29

0.16

0.07

0.10

RNA transport to uninfected cells

7.63a

8.67b

12.23c

14.71d

Envelope glycoprotein N

0.41

0.27

0.05

0.19

Membrane fusion

10.90a

12.35b

15.91c

18.48d

Protein IA

0.11

0.13

0.17

0.35

Unknown

10.38a

12.17b

15.72c

18.19d

Protein IB

0.17

0.12

0.10

0.16

Unknown

4.58a

6.32b

9.57c

10.93d

Virion protein US2

0.31

0.26

0.05

0.01

Possibly interacts with cytokeratin 18

12.06a

12.44b

16.68c

19.48d

Envelope glycoprotein G

0.08

0.10

0.12

0.14

Cell-to-cell
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US5

US6

US7

sORF1

8.38a

10.15b

13.95c

15.37d

Envelope glycoprotein J

0.59

0.24

0.17

0.14

Unknown

9.34a

11.22b

14.81c

16.74d

Envelope glycoprotein D

0.21

0.15

0.02

0.02

Cell attachment

10.63a

11.97b

15.86c

18.11d

Envelope glycoprotein I

0.16

0.18

0.19

0.08

Cell-to-cell spread

7.15a

8.74b

12.69c

14.72d

Tegument protein VP13/14

0.27
0.26
0.10
0.25
Possibly gene regulation
The expression levels of ILTV genes were presented to Cp indicated by -∆Ct + 24.
‡
a, b, c and d indicate differential expression, and they were deducted by ANOVA test in JMP
Genomics 5.0.
§
The productive proteins and their functions were referenced from the nucleotide information of
Gallid herpesvirus 1 (NC_006623) in NCBI.
†
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Table 3. The list of virus genes which were no differences of gene expression at 1 and 3 dpi in
ILTV infected chicken embryo lung cells.
1 dpi
3 dpi
5 dpi
7 dpi
Cp
Cp
Cp
Protein§
Cp†
Genes
SE‡
SE
SE
SE
Functions§
5.80a
5.43a
10.40b 13.10c
Nuclear protein UL4
UL4
0.27
0.36
0.01
0.05
Unknown
UL5

4.19a
0.43

4.50a
0.57

7.40b
0.12

10.28c
0.03

Helicase-primase helicase subunit
DNA replication

UL7

2.83a
0.73

3.78a
0.56

6.65b
1.59

12.37c
0.47

Tegument protein UL7
Virion morphogenesis

UL8

4.98a
0.49

5.38a
0.35

9.36b
0.18

10.84c
0.26

Helicase-primase subunit
DNA replication

UL10

8.49a
0.24

8.77a
0.29

11.89b
0.12

14.48c
0.01

Envelope glycoprotein M
Membrane fusion

UL13

8.01a
0.25

8.32a
0.10

12.52b
0.07

15.35c
0.16

Tegument serine/threonine protein kinase
Protein phosphorylation: PK family

UL14

7.29a
0.53

7.69a
0.22

11.99b
0.11

14.81c
0.26

Tegument protein UL14
Virion morphogenesis

UL18

7.21a
0.29

7.48a
0.43

12.35b
0.21

14.67c
0.18

Capsis triplex subunit 2
Capsis morphogenesis

UL19

6.79a
0.36

7.36a
0.32

11.87b
0.20

13.54c
0.12

Major capsid protein
Capsid morphogenesis

UL20

4.03a
0.38

4.43a
0.38

8.42b
0.13

11.75c
0.07

Envelope protein UL20
Membrane fusion

UL22

7.40a
0.79

6.32a
0.38

10.42b
0.11

13.05c
0.10

Envelope glycoprotein H
Cell entry: cell-to-cell spread

UL23

3.72a
0.41

3.17a
0.26

7.62b
0.11

11.09c
0.04

Thymidine kinase
Nucleotide metabolism

UL30

5.46a
0.53

6.08a
0.47

8.83b
0.23

10.56c
0.17

DNA polymerase catalytic subunit
DNA replication
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UL31

7.42a
0.08

7.38a
0.43

11.25b
0.06

13.97c
0.15

Nuclear egress lamina protein
Nuclear egress

UL32

5.93a
0.44

5.76a
0.22

9.41b
0.08

11.31c
0.35

DNA packaging protein UL32
DNA encapsidation

UL33

5.35a
0.04

5.54a
0.13

9.77b
0.23

11.75c
0.20

DNA packaging protein UL33
DNA encapsidation

UL34

8.67a
0.16

8.50a
0.22

12.81b
0.02

15.64c
0.01

Nuclear egress membrane protein
Nuclear egress

UL35

8.38a
0.07

8.24a
0.16

13.08b
0.02

16.43c
0.03

Small capsid protein
Capsid morphogenesis

UL36

5.31a
0.74

5.27a
1.13

9.59b
0.27

12.10c
0.13

Large tegument protein
Capsid transport

UL37

6.46a
0.26

5.76a
0.54

10.97b
0.19

13.25c
0.13

Tegument protein UL37
Virion morphogenesis

UL39

6.96a
0.08

6.54a
0.45

11.09b
0.06

12.51c
0.27

Ribonucleotide reductase subunit 1
Nucleotide metabolism

UL40

8.51a
0.45

8.24a
0.36

12.40b
0.15

14.98c
0.03

Ribonucleotide reductase subunit 2
Nucleotide metabolism

UL41

5.44a
0.20

5.55a
0.28

10.02b
0.09

13.03c
0.10

Tegument host shutoff protein
Cellular mRNA degradation

UL43

8.75a
0.23

8.23a
0.19

13.29b
0.07

15.95c
0.03

Envelope protein UL43
Possibly membrane fusion

UL46

8.35a
0.22

8.39a
0.08

12.32b
0.18

14.66c
0.05

Tegument protein VP11/12
Possibly gene regulation

UL48

6.46a
0.22

6.57a
0.11

10.58b
0.11

13.09c
0.16

Transactivating tegument protein VP16
Transactivates immediate early genes

UL51

7.55a
0.10

7.06a
0.37

11.30b
0.07

14.93c
0.02

Tegument protein UL51
Virion morphogenesis

UL53

6.14a
0.32

6.77a
0.61

9.90b
0.14

12.11c
0.04

Envelope glycoprotein K
Membrane fusion
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UL54

6.08a
0.24

6.57a
0.34

10.62b
0.10

12.89c
0.13

Multifunctional expression regulator
RNA metabolism and transport

UL56

6.78a
0.24

6.98a
0.01

9.39b
0.15

11.94c
0.08

Unknown
Possibly vesicular traffiking

ORF-C

8.07a
0.37

8.13a
0.06

11.16b
0.07

14.23c
0.02

Protein IC
Unknown

ORF-D

5.39a
0.73

5.83a
0.44

9.80b
0.08

13.29c
0.08

Protein ID
Unknown

ORF-E

6.48a
0.14

6.13a
0.21

10.56b
0.08

13.59c
0.07

Protein IE
Unknown

OEF-F

4.55a
0.53

5.27a
0.31

8.14b
0.09

11.84c
0.01

Protein IF
Unknown

US3

7.48a
0.13

7.32a
0.30

11.89b
0.06

14.61c
0.06

Serine/threonine protein kinase US3
Protein phosphorylation: apoptosis

US8

6.90a
0.21

7.19a
0.18

11.27b
0.14

13.16c
0.20

Envelope glycoprotein E
Cell-to-cell spread

US8A

7.46a
0.25

7.77a
0.23

12.32b
0.61

14.36c
0.07

Membrane protein US8A
Unknown

US10

5.44a
0.93

5.58a
0.30

10.26b
0.20

13.29c
0.02

Virion protein US10
Unknown

5.02a
6.94b
9.96c
Protein sORF3
5.32a
0.22
0.41
0.11
0.05
Unknown
†
The expression levels of ILTV genes were presented to Cp indicated by -∆Ct + 24.
‡
a, b, c and d indicate differential expression, and they were deducted by ANOVA test in JMP
Genomics 5.0.
§
The productive proteins and their functions were referenced from the nucleotide information of
Gallid herpesvirus 1 (NC_006623) in NCBI.
sORF4/3
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(B)
Genes
UL21

UL42

ICP4

1 dpi

3 dpi

5 dpi

7 dpi

Cp

Cp

Cp

Cp

Protein

SE

SE

SE

SE

Functions

1.33a

3.75b

7.09c

8.06c

Tegument protein UL21

0.32

0.19

0.35

0.45

Virion morphogenesis

8.23a

12.43b

7.92a

14.93c

0.13

0.14

0.22

0.03

DNA polymerase processivity
subunit
DNA replication

17.15a

17.67b

17.44abc

17.67bc

Transcriptional regulator ICP4

0.13

0.02

0.05

0.12

Gene regulation
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Figure 1. The virus genes indicating the unique pattern changes of gene expression at all time
points in ILTV infected chicken embryo lung cells. (A) The three genes including UL21, UL42
and ICP4 among 76 ILTV genes brought out a distinctive style at all time points. The blue line
with the closed circle, the red line with the closed square and the green line with the closed
triangle are shown UL21, UL42 and ICP4, respectively. The X-axis appears dpi as a time point,
and the Y-axis exhibits Cp values as an expression level of each gene. (B) The definite numbers
involving expression levels and standard error (SE) of each gene at each time point, expressing
proteins and protein functions are denoted. The Cp and SE values were calculated from
triplicates of biological samples, and the superscripts were drawn from ANOVA test.
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(B)
Genes

1 dpi
Cp
SE

3 dpi
Cp
SE

5 dpi
Cp
SE

7 dpi
Cp
SE

6.84a

5.89b

10.60c

12.80d

0.33

0.44

0.10

0.05

4.45a

2.49b

6.56c

8.59d

DNA packaging terminase subunit

0.43

0.13

0.25

0.37

DNA encapsidation

5.82a

4.56b

9.91c

12.42d

0.46

0.19

0.04

0.05

Single-stranded DNA-binding
pretein
DNA replication

8.17a

7.61b

11.72c

13.75d

Deoxyuridine triphosphatase

0.08

0.16

0.12

0.03

Nucleotide metabolism

4.84a

3.02b

6.88c

10.58d

Helicase-primase primase subunit

0.42

0.67

0.42

0.52

DNA replication

UL17

UL28

UL29

UL50
UL52
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Protein
Functions
DNA packing tegumnet protein
UL17
DNA encapsidation: capsid
transport

Figure 2. The five virus genes expressing down-regulation of gene expression at 3 dpi in ILTV
infected chicken embryo lung cells. (A) The expressions of the five genes named UL17, UL28,
UL29, UL50 and UL52 were once down-regulated at 3 dpi than those of 1 dpi and then
continually up-regulated until 7 dpi. The red line with the closed square, the light blue line with
the closed diamond, the green line with the closed triangle, the blue line with the closed circle,
and the purple line with the asterisk stand for UL28, UL52, UL29, UL17 and UL50, respectively.
The X-axis represents dpi as a time point, and the Y-axis signifies Cp value as an expression
level. (B) Overall, all expression levels, SE values, the names of functional proteins and the
functions of the proteins were shown up. The Cp and SE values were resulted from triplicates of
biological samples, and the superscripts were come up with ANOVA test.
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1. Abstract
A continuously growing immortal cell substrate can be utilized for viral vaccine
production based on a cell culture. The aim of this study was to establish an immortal chicken
cell line for efficient propagation of avian infectious viruses including ILTV causing acute upper
respiratory disease in chickens. Various ectopic expression plasmids containing cell cycle
stimulating genes and small interfering RNA (siRNA) expression systems targeting cell cycle
inhibitory genes were transfected into primary chicken embryo liver (CEL) cells. As results,
three immortalized chicken embryo liver (CELi) cell lines named CELi-si-p53, CELi-im and
CELi-vector were established. The CELi-im was spontaneously immortalized with no
transfection, while the CELi-si-p53 and CELi-vector were immortalized with transfection of the
expression construct for siRNA against p53 and the expression vector control, respectively. All
three CELi cell lines are permissive to ILTV infection, but low ILTV titers (~10 plaque forming
units/ml) were produced. In addition, newly immortal cell lines were permissive to MDV and
avian metapneumovirus (AMPV). To identify genetic alterations in immortal CELi cell lines,
mRNA expressions for cell cycle regulatory genes were determined during the immortalizing
progresses. Compared to those in the primary CEL counterpart, the mRNA expressions of p53,
Mdm2 and p16INK4a were down-regulated in all three CELi cell lines, while those of RB, E2F-1,
p19ARF and c-myc were up-regulated. The p21WAF1 showed up-regulation in qPCR in contrast to
down-regulation in RT-PCR results. These results are closely similar to genetic alterations found
in previously established immortal chicken embryo fibroblast (CEFi) cell lines showing efficient
propagation of MDV. Therefore, newly established CELi cell lines can serve as alternative cell
lines for vaccine production against infectious avian viruses.
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2. Introduction
The primary chicken embryo kidney (CEK), chicken embryo fibroblast (CEF) and CEL
have been preferred for virus replication, propagation, detection and even vaccine production [16]. However, the primary cultured cells directly prepared from live organ tissues have limitations
for virus propagation such as the limited life-span, time consuming and labor intensive
preparation, heterogeneous cell populations, and potential microbial contamination. Thus,
continuously growing immortal cell lines can serve as an alternative cell substrate for virus
propagation. Two immortalized avian cell lines, DF-1 derived from chicken embryo fibroblast [7]
and LMH chemically induced chicken hepatocellular carcinoma cell line [8], have been widely
used for the propagation of avian infectious herpesviruses including avian influenza, avian
broncheitis virus, MDV, AMPV and ILTV [9]. For virus propagation and vaccine production,
immortalized cell lines should not carry existing endogenous and exogenous viral genomes,
should supply homogenous cells and should overcome a disadvantage found in the use of
primary cells such as virus titer fluctuation.
To date, only two immortal CEF cell lines named DF-1 and SC-1 have been established
spontaneously without the use of tumorigenic viruses or oncogenic chemicals [7, 10]. In addition,
other CEFi cell lines such as breast CEFi (BCEFi) and heart CEFi (HCEFi) were established, but
not spontaneously [11]. Although many chicken embryo cell lines have been established and
reported, various cellular characteristics including cellular growth rate (rapid vs slow),
morphology (piling-up vs contact inhibition) and the steady state expression levels (up- vs downregulation) for various cell cycle regulatory genes are critical to determine whether the
established cell line is a tumor line or not, and in turn, whether a cell line can serve as a suitable
substrate for the vaccine production.
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Of a variety of cell cycle regulatory factors, key regulatory factors including p53, Rb,
Mdm2, E2F-1, p21WAF1, p19ARF, p16INK4a and c-myc in chicken cells were determined previously
[10-13], and those factors have been well-characterized for cell cycle regulation in mammalian
species in addition to model organisms. The tumor suppressor p53 functions in cell cycle arrest
[14], and p21WAF1 (CDK inhibitor) and Mdm2 (ubiquitin ligase) are transcriptionally upregulated by p53 protein [15-18]. Rb protein inhibits premature G1/S phase transition by binding
to E2Fs, which activate G1/S transition when E2Fs were released from phosphorylated Rb [1922]. Both p16INK4a and p19ARF were encoded at INK4a/ARF locus called CDKN2A [23]. ARF
(CDK inhibitor) acts as a tumor suppressor or to active p53-dependent cell cycle arrest [24], and
IKN4a (CDK inhibitor) is also tumor suppressor regulating the cell cycle [25]. Myc (c-myc) is a
well-known proto-oncogene and transcriptional regulator controlling cell proliferation, cell
growth, differentiation and apoptosis [26, 27].
In this study, we established three immortal chicken liver (CELi) cell lines mainly
targeting the propagation of ILTV causing acute upper respiratory disease in chickens in addition
to other avian viruses. Furthermore, the mRNA expression levels of cell cycle regulatory genes
including p53, Mdm2 and p21WAF1 (transcriptional target of p53 and CDK inhibitor), p16INK4a
and p19ARF (CDK inhibitor), Rb and E2F-1 (cell cycle progression), and c-myc (proto-oncogene),
were determined at various passages during the progression of immortalization in CELi cell lines.
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3. Materials and methods
3.1. Isolation and culture of chicken liver cells
The primary chicken embryo liver (CEL1°) cells were isolated from 15 days old chicken
embryos. Embryonic liver tissues were treated with VT solution (1:1 of 0.25% trypsine and PBS)
for 30 minutes. For cell growth and transfection, cells were plated into 100 mm tissue culture
dishes (Sarstedt, Newton, NC, USA) coated with 0.5% gelatin in PBS. The CEL cells were
cultured in Dulbecco’s Modified Eagle Medium (DMEM, 0.45% glucose with 10% of FBS, 1%
of penicillin-streptomycin and 1% of L-glutamine (Invitrogen Life Technologies, Carlsbad, CA,
USA) at 39°C and 5% CO2 in a humidified incubator. The 6x105 cells were transferred to a new
tissue culture dishes, the medium was changed every 2 days, the cells were passaged every 4-5
days after establishing immortal stage, and cell numbers were counted at every passage.

3.2. Transfection and selection
Lipofectamin2000 (Invitrogen Life Technologies, Carlsbad, CA, USA) was used for the
transfection using manufacturer’s instruction. After transfection, the 100 µg/ml concentration of
hygromycinB (EMD, Darmstadt, Germany) was used to select out untransfected cells. After
selection for 15 days, surviving cells were transferred into a new 100 mm tissue culture dish.

3.3. RNA extraction
The RNA samples were prepared at passages of 20, 50, 70 and 90 for CELi-im, passages
of 35, 50, 70 and 90 for both CELi-si-p53 and CELi-vector. Total RNA was extracted from all
three CELi cells at designated passages in addition to every tenth passgae cells using TRIzol
reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) following manufacturer’s
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instruction. The total RNA was treated with DNase I (New England BioLabs Inc., Ipswich, MA,
USA) and re-purified by TRIzol reagent. Quantity of the re-purified total RNA was measured by
Nanodrop1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA) and quality was
assessed by agarose gel electrophoresis (data not shown).

3.4. End-point reverse-transcription (RT)-PCR and quantitative RT-PCR (qPCR)
RT reactions were performed with SuperScript II RTase (Invitrogen Life Technologies,
Carlsbad, CA, USA) using 3 µg of total RNA, and the RT products were diluted to 1:10 with
DEPC-water. PCR reactions were performed by the following condition: denaturing 95°C for 30
s, annealing at 62°C for 1 min, extending at 72°C for 30 s and finally extending at 72°C for 10
min in 40 cycles and 18 cycles for chicken GAPDH (chGAPDH) which was used as an
endogenous loading control. The same RT products used in end-point RT-PCR were used for
qPCR with dyes of SYBR and reference ROX dye (Invitrogen Life Technologies, Carlsbad, CA,
USA). The qPCR reactions were performed by the following condition: 40 cycles of denaturing
95°C for 30 s, annealing at 62°C for 1 min, extending at 72°C for 30 s. A non-template control
(NTC) and chGAPDH were used for the relative quantification. The fold change values for target
gene groups comparing to the samples of CEL1° were determined by the -ΔΔCT method [28].
Moreover, gene specific primer sets for 9 genes were designed by Primer 3 software
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3.cgi) and were synthesized by Integrated DNA
Technologies (Coralville, IA, USA). Primer sequences are shown in Table 1.
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4. Results and discussion
4.1. Cellualr proliferation during immortalizing processes
Various ectopic expression constructs for cell cycle stimulating genes and siRNA
expression systems against cell cycle inhibiting genes were introduced into CEL1° cells, which
were freshly isolated from chicken embryo liver and three embryo liver cell lines were
established as immortalized cell lines. The cell lines were generated by the transfection with no
construct (spontaneous), siRNA expression vector against p53 (siRNA-p53) and vector control
(pcDNA3.1-hygro), and cell lines were named as CELi-im, CELi-si-p53 and CELi-vector,
respectively. Cells were passaged every 4-5 days until passage # 100 for more than 1 year. The
rate of population doubling (PD) per day for each cell lines was determined at every passage
(Figure 1). The CELi-si-p53 exhibited a low PD for the first 4 months until passage 30. Between
passage 31 and 48, the PD dramatically increased reaching 1.2 PD/day. After the dramatic
amplification period, the PD for this cell line fluctuated between 0.2 and 0.9 until passage 64.
Though minor fluctuations were found until passage 86, the PDs stablized around 1.2 until
passage 100 (Figure 1A). Unlike CELi-si-p53, CELi-im and CELi-vector displayed unstable cell
proliferation from early- to the passage numbers (data not shown). In CELi-im, PDs largely
fluctuated between 0.2 and 1.1 until passage 85, and became stable thereafter until passage 100
(Figure 1B). The CELi-vector cells also showed big fluctuation in PDs ranging between less than
0.1 and 1.2 until passage 61. After this unstable stage, PDs continuously increased until passage
78 with cells exhibiting stable cell proliferation until passage 100 (Figure 1C).

4.2. The morphologies and growth rates of immortal liver cell lines
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The morphologies and growth rates of the three CELi cell lines at passage 100 were
examined for 4 days (Figure 2 and 3). Though morphologies were similar between the three cell
lines, CELi-im and CELi-si-p53 were more roundish in shape and fatter compared to the thin and
small CELi-vector cells (Figure 2). After growing for 3 days, morpholgies were not
distinguishable under microscopy since culture dishes were confluent by excessive cell numbers.
Growth rates of three CELi cell lines were compared to CEL1° cells and to cells from chemically
induced chicken hepatoma cell line, LMH (Figure 3). While CEL1° and LMH cells showed no
increase in cell numbers (CEL1°) or exhibited slow growth reaching 6x105 cells from 1x105
(LMH), all three CELi cell lines showed much greater growth rates over the 4 day period
examined. Growth rates of CELi-im and CELi-vector showed similar levels at all time points,
while CELi-si-p53 exhibited slower growth than CELi-im and CELi-vector, with all 3 cultures
exhibiting much greater growth rate than CEL1° and LMH cells. The fact that newly established
CELi cell lines can proliferate stably and rapidly suggests CELi cell lines can become alternative
cellular substrates for virus propagation if cells are permissive to infection with avian viruses.

4.3. Altered expression of cell cycle regulatory genes
To characterize genetic alterations to induce rapid cell divisions in CELi cell lines,
transcriptional changes of cell cycle regulatory genes such as p53, retinoblastoma (Rb), Mdm2,
E2F-1, p21WAF1, p19ARF, p16INK4a and c-myc were determined by RT-PCR and qPCR during the
progression of immortalization. The expression level of p53 mRNA in all three CELi cell lines
was dramatically down-regulated compared to the CEL1° counterpart (Figure 4A, 5A and 6A).
Similar results were reported previously regarding immortal CEF cell lines showing that p53
mRNA expression was greatly decreased in immortal CEF cell lines [11-13]. Furthermore, the
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down-regulation of p53 is known as a key feature in the immortalization of human cells [29, 30].
Thus, the down-regulation of p53 in CELi cell lines appears to be a typical genetic alteration
process during cellular immortalization. As the result of the down-regulation of p53, the
expression of p21WAF1 and Mdm2 mRNAs, which are the transcriptional targets of p53, were
found to be down-regulated compared to the CEL1° counterpart when determined by qPCR and
end-point RT-PCR (Figure 4C and 4E, Figure 5C and 5E, and Figure 6C and 6E).
However, Rb, another tumor suppressor, was greatly up-regulated in all CELi cell lines
(Figure 4B, 5B and 6B) similar to previous reports on other immortal CEF cell lines [11]. The
increased Rb expression in immortal chicken cell lines are in contrast to its decreased expression
reported in other mammalian cancers [31]. In addition, the mRNA level of E2F-1, which is
regulated (suppressed) by binding with Rb , was up-regulated in all CELi cell lines (Figure 4D,
5D and 6D) as shown in immortal breast chicken embryo fibroblast (BCEFi) and heart chicken
embryo fibroblast (HCEFi) cell lines [11]. Generally E2Fs, including E2F-1, function in the
cellular proliferation [32]. Moreover, E2F-1 mRNA expression is down-regulated in senescent
cells of human diploid fibroblast (HDF), mouse embryonic fibroblast (MEF) and CEF [33].
According to the result of end-point PCR, the increased level of E2F-1 mRNA is much greater
than those of Rb compared to the CEL1°counterpart, and hence the absolute expression level of
E2F-1 may be much higher than Rb. Greater abundancy of E2F-1 compared to Rb suggests the
level of free, not bound to Rb, E2F-1 increased in CELi cell lines and, in turn, may stimulate
enhanced cell cycle progression in CELi cells.
According to previous reports [11, 33], the expression level of cyclin A, B2, B3, C, D1
and E were up-regulated in immortal CEF cell lines, but the expression levels of p16INK4a, one of
the cyclin dependent kinase inhibitors, was down-regulated in immortal CEF cell lines. We
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confirmed the down-regulation of p16INK4a mRNA expression in all three CELi cell lines (Figure
4G, Figure 5G and Figure 6G) in addition to forecasting the up-regulation or activation of cyclin
and cyclin dependent kinases. Interestingly, the expression patterns between p16INK4a and E2F-1
were shown in reverse directions as same as showing in the previous study [33].
The expression level of p19ARF mRNA was up-regulation in all CELi cell lines (Figure
4F, 5F and 6F). Though the major function of p19ARF is tumor suppression and induction of
apoptosis through binding to Mdm2 stabilizes p53 [34] and prevents cell proliferation [35],
recent finding of the p53-independent function of p19ARF showed ribosome biogenesis and cell
growth stimulation by binding to nucleophosmin/B23 (NPM) [35, 36]. Thus, the up-regulated
p19ARF mRNAs in CELi cells may play a role in cell growth by increasing ribosome biogenesis
and protein synthesis by binding to NPM [36].
The expression levels of c-myc mRNA were varied in the three CELi cell lines.
Compared to CEL1° counterpart, the expression levels of c-myc mRNA fluctuated during the
whole passage periods in all three CELi cell lines (Figure 4H, Figure 5H and Figure 6H). Though
c-myc is a strong proto-oncogene and shows critical functions on cellular proliferation in
mammal [26, 27], variable expression patterns found in CELi cells indicate that c-myc in avian
cells may not significantly influence cellular proliferation and immortalization.
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5. Conclusion
Three newly established CELi cell lines were found to be infection with permissive to
avian infectious viruses including ILTV, MDV, and AMPV (data not shown), but those cell lines
produced low virus titers except for AMPV propagation (data not shown). Nevertheless, CELi
cell lines are still valuable to study further virus propagation due to the rapid proliferation
potential and its morphological stability. Therefore, further research is needed to investigate
CELis’ potential as cellular substrates for the propagation and vaccine production of avian
infectious viruses.
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Table 1. The primer sets for qPCR and end-point RT-PCR.
Gene Name

Forward

Reverse

p53

CCATCCACGGAGGATTATGG

TTCAGCACCGGGGAGTAAGT

RB

TGTGCTGAGATTGGCTCACA

CTGAGAGGCGCTCTTCTTCC

Mdm2

GCCAAATTTCGGCTTGAAAA

TGTTGTTGGCTGGGAAGTTG

E2F-1

AGCGGAAGCTGAACTTGGAG CAGGAGACTTTGCCCCTCTG

p21WAF1

AAGCGTGCAGGAACCTCTTC

p19ARF

GGAAGACCTGGGAATGGATG TGATGGGTGCACCACTGAAT

p16INK4a

GCGGGATGAACTAGCCAACG GTCCGACCGAAGGAGTTGAC

c-myc

TGTCACGTCAACATCCACCA

162

CAGGACCCTCTCCCACTTGA

ACCCTGCCACTGTCCAACTT
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Figure 1. Growth curve during immortalization for chicken liver cell lines. Population doublings
(PD) per day for each cell lines were determined by passaging every 4-5 days. The X-axis
presents passage numbers, and the Y-axis indicates PD/day. (A) CELi-si-p53; (B) CELi-im; (C)
CELi-vector.
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Figure 2. The morphologies of CELi cell lines. Cells were visualized for four days using a phase
contrast microscope at 100X magnification. (A) CEL-si-p53; (B) CEL-im; (C) CELi-vector.
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Figure 3. Growth rate of CELi cell lines. Each cell line was plated at a density of 1x105 cells/6
cm dish and the number of cells was calculated every day for 4 days. X-axis indicates day, and
Y-axis depicts the number of cells. The asterisk, the closed circle, the closed triangle, the closed
square and the closed diamond indicate CELi-im, CELi-si-p53, CELi-vectors, LMH cell lines
and CEL cell line, respectively.
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Figure 4. Expression of mRNA for cell cycle regulatory genes in CELi-si-p53. The end-point
RT-PCR and qPCR results were displayed for each gene examined. X-axis indicates the passage
numbers of designated cell lines, and the Y-axis presents fold change values of relative
expression (REL). (A) p53; (B) Rb1; (C) Mdm2; (D) E2F1; (E) p21; (F) p19; (G) p16; (H) c-myc.
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Figure 5. Expression of mRNA for cell cycle regulatory genes in CELi-im. The end-point RTPCR and qPCR results were displayed for each gene examined. X-axis indicates the passage
numbers of designated cell lines, and the Y-axis presents fold change values of relative
expression (REL). (A) p53; (B) Rb1; (C) Mdm2; (D) E2F1; (E) p21; (F) p19; (G) p16; (H) c-myc.
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Figure 6. Expression of mRNA for cell cycle regulatory genes in CELi-vector. The end-point
RT-PCR and qPCR results were displayed for each gene examined. X-axis indicates the passage
numbers of designated cell lines, and the Y-axis presents fold change values of relative
expression (REL). (A) p53; (B) Rb1; (C) Mdm2; (D) E2F1; (E) p21; (F) p19; (G) p16; (H) c-myc.
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